The Master Theory: Why All Roads Lead to the Same Failure

Convergent Autophagic Collapse: Uniting Oskar Fischer’s Early Neuropathological Insights with Ralph Nixon’s Autophagy-Lysosomal Model in Neurodegenerative Disease

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

In 1907, neuropathologist Oskar Fischer described peculiar “miliary” lesions—later known as senile plaques —and neurofibrillary tangles in the brains of elderly dementia patients. His meticulous histopathological studies, though overshadowed by Alois Alzheimer’s single-case report, laid a foundational observation that such lesions correlate with cognitive decline. A century later, Ralph Nixon and colleagues advanced a molecular paradigm implicating autophagy-lysosomal failure as a root cause of neurodegeneration. This dissertation rigorously compares Fischer’s early 20th-century findings with Nixon’s 21st-century models, bridging historical neuropathology and modern molecular neuroscience. Through an extensive literature review and interdisciplinary methodology, it proposes a unifying theory of “Convergent Autophagic Collapse.” This theory posits that diverse genetic, molecular, and environmental insults—ranging from PSEN1 mutations to herpesvirus infection—converge on a common pathway of lysosomal acidification failure, leading to autophagy dysfunction and neuron death. We synthesize evidence from Fischer’s archival records and Nixon’s cutting-edge studies in cell biology to show that impaired clearance of protein aggregates within neurons is a central theme linking past and present views. Fischer’s “Fischer’s plaques” (as they were once eponymously known) represented aggregations of debris that he speculated might behave like bacterial colonies, whereas Nixon’s research demonstrates that such aggregates (e.g. Aβ-rich autophagic vacuoles) accumulate due to lysosomal breakdown in neurons. We detail how upstream events—familial Alzheimer’s genes (like PSEN1 and APP C-terminal fragments), Parkinson’s-related mutations (LRRK2, GBA1), and pathogens (HSV-1)—all trigger lysosomal dysfunction. Microscopic evidence from human autopsy tissue and transgenic models is integrated to illustrate an “inside-out” progression: neurons filled with undigested substrates (autophagic vacuoles laden with amyloid/tau or α-synuclein) ultimately rupture, giving rise to extracellular plaques and pathologies. The proposed Convergent Autophagic Collapse model thus reconciles Fischer’s early insight that something “foreign” accumulates in dementia brains with Nixon’s demonstration that failing intracellular digestion is the instigating event. By uniting historical and modern perspectives, this work argues that autophagy-lysosomal failure is a final common pathway in neurodegeneration. This insight has profound implications: it redirects the quest for Alzheimer’s etiology toward a systems-level failure of proteostasis and suggests new therapeutic angles targeting lysosomal acidification and autophagy enhancement. The conclusion calls for recognizing Fischer’s prescient contributions in light of current knowledge and for pursuing interventions that shore up the cell’s own waste-disposal system as a strategy to combat Alzheimer’s disease and related dementias.

Introduction

Neurodegenerative diseases such as Alzheimer’s disease (AD) have long been characterized by hallmark lesions—amyloid plaques and neurofibrillary tangles—first described in the early 1900s. The history of AD’s discovery is famously entwined with two scientists: Alois Alzheimer, who in 1906 reported a single case of “presenile dementia” with microscopic changes, and Oskar Fischer, who in 1907 published a far more extensive study of “senile” dementia in numerous cases¹¹¹. Fischer’s detailed accounts of what he termed “miliare Nekrosen” (miliary necrosis with drusiform neurofibrillary proliferation) captured the very plaques that would later bear Alzheimer’s name¹²¹³. Over the ensuing century, research into AD oscillated between neuropathological description and biochemical mechanism. By the late 20th and early 21st centuries, a new paradigm emerged implicating disruptions in the cell’s autophagy-lysosomal pathway as a pivotal event in neurodegeneration⁴⁵. This paradigm shift is epitomized by the work of Ralph A. Nixon, whose studies revealed that failures in neuronal autophagy – the process by which cells degrade and recycle components – underlie the accumulation of toxic protein aggregates in AD⁵¹⁴. This dissertation seeks to bridge the history of neuropathology with modern molecular neuroscience by directly comparing Fischer’s early 20th-century findings to Nixon’s autophagy-centered model, and by proposing a unified theory of disease mechanism called “Convergent Autophagic Collapse.” The core idea is that disparate upstream factors in neurodegenerative diseases all converge on a common pathway: the collapse of autophagy due to lysosomal dysfunction, leading to the catastrophic accumulation of undegraded material and eventual neuronal death. This theory aims to synthesize historical observations with cutting-edge research: for example, Fischer’s speculation that plaques might represent a reaction to a microbial “germ”⁷ can be reinterpreted through Nixon’s lens as the cell’s reaction to internal threats it cannot clear. In essence, what earlier pathologists saw as mysterious foreign bodies in the brain may actually be the consequence of the cell’s failure to digest its own contents. We proceed with a structured analysis: Introduction outlines the rationale and aims. The Literature Review situates Fischer’s and Nixon’s work in the broader historiography of AD research, examining how understanding of plaques, tangles, and intracellular waste disposal evolved over time. The Methodology explains our interdisciplinary approach, combining archival historical research with analysis of molecular neuroscience literature. In the Main Chapters, we present analytical comparisons and new synthesis: Chapter 1 examines Fischer’s early findings in depth and their immediate historical impact; Chapter 2 delineates Nixon’s autophagy-lysosomal model of neurodegeneration and supporting evidence; Chapter 3 analyzes specific upstream events (genetic mutations, pathogens, and other triggers) that cause autophagy-lysosomal failure, integrating evidence from model organisms and human studies; Chapter 4 proposes the unified framework “Convergent Autophagic Collapse,” merging insights from Chapters 1–3 into a single theory. Finally, the Conclusion reflects on how this unifying theory advances our understanding of neurodegenerative disease causation and what it means for future research and therapy. Through this work, we aim to honor historical insights (many long-neglected due to scientific and sociopolitical reasons) and illuminate how they foreshadow today’s discoveries. By comparing Fischer and Nixon, we demonstrate that despite the century separating them, both identified the accumulation of indigestible material inside neurons as a central event in dementia. Fischer observed it with a light microscope and saw “nodular” debris; Nixon observes it with electron microscopes and sees autophagic vacuoles and lysosomal aggregates. The convergence of these perspectives guides us to a new theory that not only explains the past and present data, but also provides a roadmap for addressing neurodegenerative diseases as failures of the neuron’s housekeeping systems. In doing so, this dissertation contributes to both the history of science—resituating Oskar Fischer as a co-founder of AD research—and to molecular neuroscience by refining our conceptualization of the disease mechanism driving neuronal death in AD and related disorders.

Literature Review: From Miliary Plaques to Lysosomal Failure

Historical Neuropathology of Dementia (1900–1920): The turn of the 20th century was a fertile period for neuropathologists studying senile dementia. Alois Alzheimer’s 1907 report of a “peculiar disease” in a 51year-old (Auguste D.) introduced the world to neurofibrillary tangles and what he described as “miliary foci” (small nodular deposits) in the cortex¹⁵. However, in that same year, Oskar Fischer in Prague was conducting a far broader clinicopathological investigation. In 1907 Fischer published findings from 16 cases of senile dementia, meticulously describing what he termed “miliary necroses with drusiform (nodular) proliferation of neurofibrils”¹². These lesions correspond to what we now call senile plaques. Fischer noted a necrotic core surrounded by radiating fibrillar structures, and he explicitly found such plaques in 12 out of 16 dementia cases, while finding none in non-demented control brains¹²¹⁶. He even staged the development of plaques, observing what appeared to be an initial “small star-like formation” of fibrils coalescing into larger deposits over time¹⁷¹⁸. By 1910, Fischer expanded his study to 275 brains, confirming the plaque findings in 56 dementia cases and reporting that about 17% of those cases also showed the “coarse fibrillary proliferation” in neurons that corresponds to tangles¹⁹¹¹. In other words, Fischer firmly established that plaques and tangles co-occur in senile dementia, effectively laying out the pathology of what we now term Alzheimer’s disease. Fischer’s interpretations were ahead of their time. He viewed plaques as a degenerative process of neural elements: in his view, dystrophic neuronal processes produced the plaques²⁰²¹. He described stages I through V of plaque maturation: from tiny “star-like” clusters of fibrils (Stage I) to larger “morning-star” fused clusters (Stage II), then developing a central core (Stage III “spoke formation”), progressing to a “wheel-like” stage (Stage IV) and finally “large drusige (druse) plaques” (Stage V) with a homogeneous dense core¹⁷¹⁸. This progressive staging suggested to Fischer that plaques formed endogenously over time as neurons underwent pathological changes. Notably, Fischer remarked that the smallest plaques often had a filamentous, colony-like appearance “reminding one of a bacterial colony”²². Indeed, both Fischer and some contemporaries speculated on a possible microbial role in dementia. Fischer pointed out the resemblance of plaques to microbe colonies²³, and others like Friederich Lewy and Santiago Ramón y Cajal debated whether an infectious agent could be involved in senile plaque formation. This early germ hypothesis in AD research, championed by Fischer, posited that plaques might be a reaction to chronic infection or even composed of microorganisms⁷. Alois Alzheimer himself, in a 1911 paper, acknowledged Fischer’s view that plaques might originate from something akin to bacterial colonies²³, though Alzheimer personally leaned toward a degenerative origin of fibrils within neurons²⁴. Despite Fischer’s substantial contributions, historical circumstances led to his marginalization. After 1910, Emil Kraepelin named the “Alzheimer’s disease,” crediting Alzheimer as the discoverer and largely sidelining Fischer’s work²⁵. Fischer, who was Jewish, saw his career curtailed by World War I and later by antisemitic policies; he was forced out of his position by 1939 and perished in the Theresienstadt concentration camp in 1942²⁶. Consequently, his scientific legacy languished. For several years after 1907, plaques were actually referred to as “Fischer’s plaques” in the literature²⁷, and Alzheimer himself in 1911 used that term²⁸, acknowledging Fischer’s priority in detailing them. However, by the mid-20th century, Fischer’s name faded from citation. Historiographically, it was not until recent decades that scholars began to rediscover Fischer. As one recent review noted, “it will certainly remain to Fischer’s credit that he was the first to emphasize the importance of the plaques to the histological appearance of senile dementia”²⁹. Indeed, modern historians and neuroscientists now recognize that Fischer was effectively a co-discoverer of Alzheimer’s disease³⁰, having described the same key lesions and more cases than Alzheimer, with remarkable insight. The literature review by Goedert (2009) and others chronicled this “forgotten history,” illustrating how Fischer’s meticulous drawings and staging of plaques presaged later findings of plaque heterogeneity (diffuse vs. cored plaques, etc.)³¹³². Following Fischer and Alzheimer, research into dementia pathology slowed during the mid-20th century, but some advances were made. In 1927 and 1934, Jean Vincent Divry applied Congo red dye to senile plaques and first identified their amyloid nature (birefringence under polarized light)³². By 1968, the protein composition of plaques (amyloid-β peptide, or Aβ) was being uncovered, although the full sequencing of Aβ and identification of the amyloid precursor protein (APP) came in the 1980s (Glenner and Masters, 1984). Neurofibrillary tangles were found to be composed of an abnormal form of tau protein by 1986 (GrundkeIqbal et al.). Thus, biochemical characterization of Fischer’s “peculiar substance” in plaques²⁴ took nearly eighty years. Throughout this period, however, the prevailing paradigm in Alzheimer research was the “amyloid cascade hypothesis”—the idea that accumulation of Aβ (amyloid) is the primary trigger of neurodegeneration. First formally articulated in the early 1990s, this hypothesis was driven by genetic discoveries (mutations in APP and PSEN1/2 cause early-onset AD) and by observations that Aβ is toxic to neurons. Yet, even as the amyloid theory gained dominance, some researchers noted inconsistencies (for instance, amyloid plaque burden does not always correlate with clinical dementia severity)³³. By the 2000s, mounting evidence suggested that downstream processes like protein clearance, inflammation, and oxidative stress significantly contribute to neurodegeneration³⁴³⁵. It is in this context that Ralph Nixon’s work on the autophagy-lysosomal system emerged, adding a new dimension to the literature. Emergence of Autophagy-Lysosomal Hypotheses (1980s–2010s): Autophagy, literally “self-eating,” is the cellular process for degrading and recycling intracellular constituents through lysosomes. While autophagy was recognized in the 1960s (de Duve, Ashford & Porter)³⁶, its relevance to neurodegenerative disease became evident only later. Neurons are particularly reliant on autophagy because they are long-lived, postmitotic cells that must manage and dispose of proteins and organelles over an entire lifetime³⁷. In the 1980s, some neuropathologists observed lysosomal storage-like phenomena in aged or diseased neurons (e.g. accumulation of lipofuscin). By the 1990s, Nixon and colleagues began systematically studying the endosomal-lysosomal system in AD. Cataldo and Nixon (1991, 1994) reported enlarged endosomes in neurons from AD brains, indicating perturbed endocytic trafficking. They also found elevated levels of lysosomal enzymes and hydrolases in vulnerable neurons, suggesting a compensatory response or stress on the degradation system³⁸. In parallel, electron microscopy studies showed an abundance of autophagic vacuoles in dystrophic neurites within AD plaques³⁹¹⁴. Anne Cataldo, Ralph Nixon and

others published landmark papers around 1996–2000 demonstrating that AD brains have impaired

autophagic flux: autophagosomes (the initial sequestering vesicles in autophagy) accumulate but do not properly mature into degradative autolysosomes¹⁴⁴⁰. These early findings hinted that neurons in AD were initiating autophagy (perhaps in an attempt to clear Aβ and defective organelles), but the process was stalling before completion. The result was an “autophagic pathology”: large numbers of autophagic vacuoles laden with partially digested cargo accumulating inside dystrophic neurons⁴¹¹⁴. The field truly coalesced around the autophagy-AD connection in the 2000s. In 2005, Nixon et al. published an influential immuno-electron microscopy study definitively showing extensive autophagy in Alzheimer’s disease neurons⁴²³⁹. They found that autophagosomes and related vesicles were uncommon in normal aging brains but abundant in AD, especially in neuritic processes and synaptic terminals of affected cortical neurons⁴³⁴⁴. These autophagic vacuoles (AVs) in AD contained markers like LC3 (an autophagosome protein) and cathepsin D (a lysosomal enzyme), confirming their identity⁴³. Importantly, the study noted

that most AVs in AD brains appeared immature (autophagosomes or amphisomes rather than fully

acidified autolysosomes) and that lysosomes and dense bodies also accumulated in those neurites⁴¹ ⁴⁵. The authors concluded that transport and maturation of autophagic vacuoles was likely impaired, leading to a backup of undegraded material inside neurons¹⁴⁴⁰. They presciently suggested that this defect would “impede the suspected neuroprotective functions of autophagy” and could contribute to neurodegeneration¹⁴⁴⁰. Around the same time, parallel evidence emerged in other neurodegenerative diseases: for example, in Huntington’s and Parkinson’s disease models, dysfunctional autophagy was observed, linking the broader concept of proteostatic failure to neuron death⁴⁶³⁸. Ralph Nixon became a leading proponent of the idea that lysosomal proteolysis failure is a primary cause of AD. In a 2013 review in European Journal of Neuroscience, he argued that autophagy failure— particularly due to defective lysosomal acidification—is a critical upstream event in AD pathogenesis⁴⁷. That review (as cited in subsequent literature) emphasized how familial AD mutations in PSEN1 (presenilin-1) cause lysosomal pH elevation and autophagy dysfunction⁴⁷. Indeed, Nixon’s group had demonstrated that Presenilin-1, beyond its role in generating Aβ, is required for lysosome acidification by facilitating the assembly and trafficking of the proton pump v-ATPase⁴⁸⁴⁹. This finding provided a direct mechanistic bridge between the genetic and pathological facets of AD: the PSEN1 gene that mutated in Alzheimer’s families doesn’t just cause more amyloid, it also cripples the cell’s garbage disposal (lysosome) by preventing proper acidification⁸⁵⁰. Other studies around that time (e.g. Boland et al., 2008) reinforced that neurons under stress ramp up autophagy, but in AD models they fail to complete it⁵¹⁵². By the late 2010s and into the 2020s, the autophagy-lysosomal perspective has become mainstream in neurodegeneration research. Terms like ALP (autophagy-lysosomal pathway) dysfunction, endolysosomal trafficking defects, and even specific phenomena such as PANTHOS (“poisonous flower” pattern of extreme autophagy pathology) have entered the lexicon⁵³⁵⁴. In 2022, a groundbreaking Nature Neuroscience study from Nixon’s group directly visualized lysosomal pH deficits in AD model mice and showed that those deficits precede and predict amyloid plaque formation⁵⁵⁵⁶. They identified partially acidified autolysosomes (pa-ALs) accumulating months before extracellular plaques appeared, and demonstrated that impaired lysosomal v-ATPase activity in neurons correlates with age and plaque burden ⁵⁷⁵⁶. In human AD brains and advanced models, Nixon and colleagues observed the PANTHOS phenomenon: neurons loaded with perinuclear clusters of autophagic vesicles that internally accumulate Aβ (forming a “flower-like” wreath) and eventually lyse, releasing plaques⁵⁸⁵⁹. This suggests an “insideout” mechanism of plaque origin: plaques may largely derive from the remnants of dying neurons that succumb to autophagic buildup⁵⁹⁵. Such insights mark a notable departure from earlier thinking that plaques form purely by extracellular aggregation of secreted Aβ; instead, it appears that failing autophagy causes neurons to fill with amyloid internally and burst. In summary, the literature shows a clear trajectory: Early 20th-century neuropathologists like Fischer

documented the morphology of proteinaceous accumulations in dementia, while early 21st-century

researchers like Nixon uncovered the cellular process failures leading to those accumulations. Historiographically, we see a convergence of ideas: Fischer’s notion of an inherent degenerative process producing plaques aligns remarkably with Nixon’s evidence of an internal clearance failure producing plaques. The concept of an infectious process (the “germ” hypothesis) that Fischer entertained⁷ can be mapped onto modern findings that microbes (like viruses or spirochetes) might precipitate autophagy defects, effectively “seeding” the pathology (a point we will explore in Chapter 3). This literature review underscores that an integrative approach—honoring both the histology and the cell biology—is essential to fully understand neurodegenerative disease mechanisms. The stage is now set to delve deeper into the specific contributions of Fischer and Nixon, and to integrate them into a coherent theoretical framework.

Methodology: Integrating Historical and Molecular Analyses

This dissertation employs an interdisciplinary methodology, combining historical research methods in the

history of science with molecular neuroscience analysis. The approach is two-pronged: (1) a

historiographical analysis of early 20th-century neuropathology sources (with a focus on Oskar Fischer’s work), and (2) a critical review and synthesis of 21st-century experimental research on autophagy-lysosomal mechanisms in neurodegeneration. Historical Research Methods: We conducted archival and literature research on primary and secondary sources related to Oskar Fischer and early Alzheimer research. Key primary sources included Fischer’s original German publications from 1907 and 1910 (accessed via translations and reprints, e.g., in The Early Story of Alzheimer’s Disease compendium⁶⁰⁶¹). We also examined writings by contemporaries (Alois Alzheimer’s 1907 and 1911 papers, Kraepelin’s 1910 textbook entries, and works by Perusini, Bonfiglio, etc.) to contextualize Fischer’s findings. Because Fischer’s works were in German Gothic script and not readily accessible, we relied on published English translations and analyses by historians (such as Goedert 2009, Bick et al. 1987, and Engelhardt 2023) to ensure accurate interpretation of his terminology (e.g., “drusige Nekrose” meaning drusiform necrosis, “Sphaerotrichia cerebri” for filamentous spheres, etc.). We applied historiographical methods to understand how Fischer’s contributions were received (or neglected) in subsequent decades. This involved reviewing historical narratives and biographies that address why Fischer’s plaques were eclipsed by Alzheimer’s name, including the role of scientific credit, wartime disruptions, and biases (such as antisemitism) that affected citation practices³⁰. By examining citations in journals from 1907–1920, we tracked the usage of terms “Fischer’s plaques” vs “Alzheimer’s disease,” gaining insight into the scientific discourse of the time. In our historical analysis, we take a constructivist approach that considers the development of scientific ideas in context. We treat Fischer’s interpretations (e.g. the “bacterial colony” analogy for plaques⁷) not as naïve mistakes but as hypotheses shaped by the knowledge available in 1907 (when microbiology was ascendant). We compare these with Alzheimer’s interpretations and note their divergence (Fischer’s view of plaques as possibly exogenous vs Alzheimer’s as endogenous degenerative products²⁴⁶²). We also leverage visual analysis of Fischer’s published drawings and diagrams (sourced from reprinted figures in modern articles²⁰²¹) to understand what he observed under the microscope. These visual materials are treated as data in themselves; for example, we analyze Fischer’s schematic stages of plaque formation and compare them to modern classifications of diffuse vs neuritic plaques. Molecular and Analytical Methods: On the scientific side, we performed a comprehensive literature review of experimental studies (1980s–2025) on autophagy, lysosomal function, and neurodegeneration. We systematically searched databases (PubMed, Web of Science) for terms such as “autophagy Alzheimer’s,” “lysosomal Alzheimer Nixon,” “Presenilin lysosome autophagy,” “HSV-1 Alzheimer autophagy,” “LRRK2 lysosome,” etc., ensuring we included the most recent findings up to late 2024. We gave particular priority to peer-reviewed journal articles by Ralph A. Nixon and colleagues, since his work is central to the modern aspect of our comparison. These include pivotal papers like Ju-Hyun Lee et al., 2010 (Cell) demonstrating Presenilin-1’s role in lysosome acidification⁴⁸⁴⁹, Boland et al., 2008 (J. Neurosci) on autophagic flux in neurons⁵¹⁵², and the recent Acta Neuropathologica 2024 review by Nixon⁵¹⁰. We also reviewed studies linking other genetic factors (e.g. APP, LRRK2, GBA1) and pathogens to autophagy dysfunction, pulling from a broad range of journals. For each of the upstream factors of interest (e.g., Herpes simplex virus 1, presenilin mutations, etc.), we critically evaluated evidence for how it impacts the autophagylysosomal pathway. This meant reading virology studies showing HSV1 impairs autophagosome-lysosome fusion⁶³⁶⁴, or cell biology experiments demonstrating LRRK2 mutations alter lysosomal acidity and autophagic flux⁶⁵⁶⁶. Our analytical method in synthesizing these studies was to use a causal network analysis: we constructed a conceptual map linking upstream events to downstream cellular effects to ultimate neurodegenerative outcomes. For example, we mapped how a PSEN1 mutation leads to defective v-ATPase glycosylation (cause) which leads to lysosomal pH increase (mechanism), causing autophagic build-up of APP-βCTF and Aβ (effect), which triggers neuronal toxicity (outcome)⁸⁴⁹. We repeated this exercise for each factor (HSV-1, LRRK2, GBA1, etc.), then looked for common nodes in these pathways – these commonalities form the backbone of our “Convergent Autophagic Collapse” theory. This approach is inherently comparative: we constantly cross-reference how different triggers converge on similar cellular phenomena (e.g., lysosomal membrane permeabilization, cathepsin leakage, impaired proteolysis). Throughout, we maintain a critical lens on sources. When dealing with contemporary science papers, we assess their experimental robustness (e.g., whether findings were reproduced in multiple models or labs) and note points of controversy (for instance, a 2011 study questioned Nixon’s finding about autophagy being impaired in presenilin deficiency⁶⁷, which we address in our analysis to ensure balance). We also

integrate evidence from multiple experimental modalities: light and electron microscopy (for

morphological data), biochemical assays of enzyme activity (for functional lysosomal data), in vivo mouse model phenotypes, and human post-mortem biochemical analyses. This multimodal evidence is crucial to strengthen causal inference. For example, if cell culture shows HSV1 blocks autophagy, we also look at mouse or human data linking HSV1 infection to AD pathology⁶⁸. Finally, our methodology includes constructing a unifying model diagram (conceptually) which we describe in Chapter 4. Although not an “experiment” per se, this model-building is a methodological step where we integrate findings into a coherent theoretical framework. We follow principles of scientific modeling: consistency with known data, explanatory power for disparate observations, and testable predictions. For instance, the Convergent Autophagic Collapse model predicts that enhancing lysosomal acidification should mitigate pathology across different neurodegenerative diseases – a prediction we note has experimental support (e.g., enhancing v-ATPase function or lysosomal proteolysis shows neuroprotective effects in multiple models⁶⁹¹⁰). In summary, the methods of this work span historical textual analysis and scientific data synthesis. By combining these, we ensure that our comparisons between Fischer and Nixon are not anachronistic; we interpret Fischer’s observations in the light of his time, then re-interpret them with modern knowledge, and likewise view Nixon’s discoveries with an appreciation for the foundational observations that came long before. This integrated methodology enables a richly contextualized answer to our research question and lends credibility to the unifying theory we propose.

Chapter 1: Oskar Fischer’s Early Neuropathological Findings and Theories

In this chapter, we delve into Oskar Fischer’s original observations and interpretations, analyzing their content and significance in detail. The goal is to extract from Fischer’s work the essence of what he discovered about neurodegenerative pathology and what hypotheses he ventured, then to lay these out clearly as a basis for later comparison with modern ideas. 1.1 Fischer’s Microscopic Observations – Plaques and Tangles: Fischer’s 1907 paper (published in German in Monatsschrift für Psychiatrie und Neurologie) is remarkable for its systematic approach. Examining aged brains from a Prague asylum, Fischer identified numerous small lesions in the cortical gray matter of patients with senile dementia. Under silver staining (likely Bielschowsky’s silver method, common at the time), these lesions appeared as “miliary necroses” – tiny foci of what looked like degenerating tissue⁷⁰. Fischer provided meticulous drawings: in one illustration, he shows a neuron surrounded by a dense meshwork of argyrophilic (silver-staining) fibrils, some with swollen varicosities²⁰²¹. He noted a central area that took on a blob-like homogeneous staining (the plaque core) and peripheral filaments radiating out (dystrophic neurites). Crucially, Fischer recognized these structures as consistent features in dementia. He reported finding an average of 15 such plaques per brain slice in dementia cases versus almost none in non-demented controls¹²⁷¹. This quantification already implied a disease association. Fischer also confirmed the presence of neurofibrillary tangles in many of the same cases. He described “coarse fibrillary proliferation” inside some neuronal cell bodies – what we know as tangled, twisted fibers accumulating in neurons¹¹⁷². He connected these two lesions (plaques and tangles), observing that about 10 of his cases showed both, while others showed only plaques. Fischer’s insight was that plaques

correlate with advanced age and cognitive decline, whereas tangles (which he sometimes called

“fibrillary degenerations of ganglion cells”) were present in a subset, perhaps indicating a particular severity or stage¹¹⁷². Notably, later research vindicated this: we now understand that practically all AD cases have both plaques and tangles, but plaques can appear earlier (even in cognitively normal elderly with amyloid pathology), while tangles correlate more tightly with clinical dementia. Fischer’s data in 1910 already hinted at this difference by noting some senile cases had abundant plaques but few tangles⁷³. Beyond simply cataloguing these lesions, Fischer attempted to classify and stage plaque development. As detailed in the literature review, he defined five progressive “stages” (I through V) in what he believed was a continuum of plaque formation¹⁷¹⁸. In Stage I (“little star”), one sees a small cluster of argyrophilic fibrils in a starburst pattern. Stage II (“morning star”) involves multiple star-like clusters merging. By Stage III (“spoke formation”), there is a clear central area (which Fischer interpreted as a developing necrotic core) with spokes of fibrils emanating. Stage IV (“wheel”) shows a denser core and a spherical outline, and Stage V (“large druse”) is a fully formed plaque with a homogeneous dense center⁷⁴⁷⁵. Fischer even subdivided Stage V into an amyloid-rich core type (Va) and a fibrillar tangle-rich type (Vb)⁷⁶⁷⁷ – presaging the modern distinction between plaques with or without a dense amyloid core, and possibly between what we now call “neuritic plaques” (with amyloid core and surrounding dystrophic neurites) and other plaque types. It is striking how Fischer’s qualitative observations align with later quantitative histological categories: for example, in modern neuropathology, diffuse plaques (lack a dense core) could correspond to Fischer’s earlystage “morning stars,” while cored plaques (dense amyloid center with dystrophic neurites) correspond to his “large druse” with bulbous neurites (Stage Vb)¹⁸⁷⁷. Fischer’s staging led him to believe that plaques were lesions that form and grow over time in the brain, rather than incidental deposits. He wrote that the stages “formed a continuum covering early to late clinical phases” of dementia¹⁷, indicating he thought plaque accumulation was part of disease progression. Modern longitudinal PET imaging of amyloid in living patients indeed shows amyloid plaque burden increases over time in Alzheimer’s, echoing Fischer’s inference. He essentially anticipated the concept of a time-course of pathology. 1.2 Fischer’s Interpretation – Degeneration or Infection?: When it came to explaining what these plaques were, Fischer offered multiple thoughts. Primarily, he saw them as a manifestation of neuronal dystrophy. In his words, there was a “nodular proliferation of neurofibrils” – suggesting that the nerve cell’s own fibrils (cytoskeletal elements) were somehow overgrowing or piling up abnormally¹²⁷⁸. He made a point that the “material” in plaques did not seem to be exactly the same as normal neurofibrils; he speculated it could be a new substance produced as part of the pathology²⁴⁶². This aligns with his Stage Vb description of “thick fibrous tangles” making up a plaque’s core⁷⁷. We can see this as an early inkling that the plaques contained some kind of aggregating proteinaceous substance (in reality amyloid, though Fischer of course didn’t know the chemistry). He was correct that it was not just regular nerve fibers. At the same time, Fischer did not dismiss an exogenous influence. The oft-cited quote is that Fischer noted the smallest plaques remind one of a “bacterial colony”²²⁷⁹. In one passage, Fischer wrote: “the formation [plaque] could be compared to colonies of microorganisms under the microscope, although no actual microbes could be ascertained”²³. This remark indicates he actively looked for microbes (like a stainable bacterium or fungus) within plaques, but found none identifiable. Nonetheless, the resemblance led him to hypothesize that perhaps a microbe or chronic infection triggers these lesions. It’s important to understand the context: circa 1907, infectious etiologies were being discovered for many chronic illnesses (e.g., syphilis for general paresis of the insane). Fischer’s contemporary, Alois Alzheimer, in 1911 discussed Fischer’s view, noting that Fischer “pointed out their similarity to bacterial colonies” and considered that in his discussion on plaque origins²³⁸⁰. Alzheimer himself was more cautious; he leaned toward the idea that plaques (and tangles) were products of degeneration of the neuron’s own fibrils (he described tangles as modified neurofibrils)²⁴⁶². The two men thus represented two hypotheses: intrinsic degeneration vs. extrinsic infection. Fischer actually encompassed both ideas: he clearly saw plaques as degenerative by nature (since he detailed how neurons nearby were dystrophic, axons ending in bulbous swellings around plaques), but he remained open to the idea that an infection could cause that degeneration. Fischer’s reports also hint at involvement of other brain cells. He noted the presence of glial cells around plaques, sometimes describing them as reactive. Later in 1912, Beljahow and Marinesco would call these plaques “gliosemiliare Knötchen” implying a glial reaction. Fischer didn’t extensively study microglia or astrocytes (the concept of microglia as immune cells wasn’t fully recognized then), but his mention of “nodular proliferation” could also reflect glial nodules. He basically saw a necrotic focus (hence the term necrosis) being encapsulated by or associated with glial or fibrillar reaction. This aligns to some extent with how we now see plaques as focal points of glial activation (microglial and astrocytic processes congregate around amyloid deposits). Summarizing Fischer’s theoretical stance: he posited that senile dementia involved a pathological process in which neurons undergo fibrillar degeneration, producing tangles inside cells and releasing fibrillar, possibly amyloid, material outside cells forming plaques. He thought this process might be set in motion or exacerbated by something like an infection, though direct evidence of microbes was lacking⁷⁸¹. In essence, he hypothesized a convergence of internal degeneration and potentially external trigger – an intriguing foreshadowing of the idea that internal proteostatic failure (degeneration) might be kicked off by external factors (like microbes). We will later see that this resonates with modern theories that pathogens like HSV-1 contribute to AD by causing autophagy disruption⁶⁸. 1.3 Reception and Legacy: It’s important to highlight how Fischer’s peers received his findings, as it sheds light on the scientific thinking of the era. In 1909, Nicolás Achúcarro and Gaetano Perusini, working with Alzheimer, also studied plaques. Perusini in 1910 published cases that reinforced the existence of plaques and tangles in “Alzheimer’s disease” (the term presenile dementia was being replaced). Perusini cited Fischer’s work and essentially confirmed it. There was little doubt even then that Fischer had found something real and significant. Alzheimer himself gave Fischer credit in his 1911 monograph by calling plaques “Fischer’s plaques”²⁸ and praising Fischer’s detailed descriptions²⁹. However, with Alzheimer’s untimely death in 1915 and Fischer’s marginalization post-WWI, further work on plaques stagnated. In the 1920s and 30s, as mentioned, progress was mostly chemical (staining properties). The term “drüsige Nekrose” (drusiform necrosis) gradually gave way to “senile plaque” as the standard nomenclature. It wasn’t until much later, after Alzheimer’s disease became widely recognized as a distinct condition in the 1970s (thanks in part to Katzman’s work reframing it as common, not rare), that historical accounts revisited the contributions of earlier scientists like Fischer and Perusini. The overshadowing of Fischer also meant that his interpretations did not directly influence mid-century research. For instance, the infection hypothesis in AD lay largely dormant for decades (aside from occasional suggestions about viruses in the 1980s). It is poignant that only in recent years, with the advent of findings on microbes in AD brains (e.g., HSV-1 DNA in plaques⁶⁸, spirochetes in AD brain tissue⁷), that Fischer’s century-old speculation is being taken more seriously again. His name appears now in context of that hypothesis—some authors refer to the “Oskar Fischer hypothesis” when discussing microbial causation of AD³⁴. In summary, Oskar Fischer discovered the cardinal lesions of AD in multiple cases and provided an interpretative framework that combined degenerative changes and possible external triggers. His concept of plaque development and importance was very advanced, even if the tools of his time limited his ability to identify the molecular nature of those lesions. Fischer essentially presented a picture of neurons failing and leaving behind debris (plaques), which captures a key idea: that these proteinaceous aggregates are tombstones of neuronal processes. The nuances of his view – such as linking plaques to age (he even used the term “presbyophrene dementia” for senile dementia) and the suggestion of a chronic disease process – are all consistent with how we see Alzheimer’s today: an age-related chronic process of neurodegeneration. Fischer’s work laid a descriptive foundation. In the next chapter, we will shift to the modern era to examine how Ralph Nixon’s investigations elucidate the mechanisms underlying similar phenomena (accumulation of intracellular debris and plaques), providing a mechanistic depth to what Fischer observed empirically. We will see that many of Nixon’s findings, when translated back into Fischer’s terms, sound like answers to questions Fischer could only pose. For instance, “What causes those drusiform deposits in the brain?” – Nixon’s answer: the collapse of the lysosomal system causing buildup of undegraded material.

Chapter 2: Ralph Nixon’s Autophagy-Lysosomal Model of Neurodegeneration

This chapter explores the work of Ralph A. Nixon and colleagues, who have been at the forefront of linking autophagy-lysosomal pathway dysfunction to Alzheimer’s disease and other neurodegenerative disorders. We will outline the core components of Nixon’s model, review the key experimental evidence supporting it, and highlight how this model reframes our understanding of plaque and tangle formation as consequences of a cellular digestion failure. 2.1 Autophagy-Lysosomal Pathway (ALP) in Neurons – A Primer: Before delving into Nixon’s findings, it’s helpful to recap what the autophagy-lysosomal system entails, especially in neurons. Autophagy is a cellular process for degrading and recycling cytoplasmic contents. The most studied form, macroautophagy, involves the formation of a double-membraned vesicle called an autophagosome that engulfs organelles or proteins, then fuses with a lysosome (an acidic, enzyme-filled organelle) to form an autolysosome, where the contents are broken down (see Figure 1). Neurons rely on autophagy to remove old or damaged mitochondria, misfolded proteins, and other debris, since neurons cannot dilute cellular waste by cell division and must survive for the organism’s lifetime³⁷. Autophagy in neurons is also a key response to stress – for example, during metabolic stress or protein aggregation stress, neurons ramp up autophagic flux to cope. Figure 1: Schematic of the macroautophagy pathway. In macroautophagy, a phagophore (curved membrane, Ph) nucleates and expands to sequester cytosolic components (organelles, protein aggregates) into an autophagosome (AP). The autophagosome then fuses with a late endosome or directly with a lysosome (LY) to form an autolysosome (AL), wherein acidic hydrolase enzymes degrade the cargo. Efficient autophagy requires proper acidification of autolysosomes by the vacuolar H⁺-ATPase (proton pump). Neurons, which have long axons, often see autophagosomes form distally and then undergo fusion and maturation as they are transported to the soma⁵⁹. Defects at any stage (formation, transport, fusion, or acidification) can lead to accumulation of autophagic vacuoles and incomplete digestion of substrates.* ⁸²¹⁰ One particularly important aspect in neurons is that autophagosomes often form in the remote parts of the cell (neurites, synaptic terminals) and then are transported to the cell body, maturing along the way⁶⁹. If transport or fusion is impaired, autophagosomes can accumulate in neurites. Another key aspect is lysosomal acidification: lysosomal enzymes (proteases like cathepsins) only work at low pH (~4.5–5). The lysosome’s acidity is maintained by the vacuolar ATPase (v-ATPase) proton pump on its membrane⁸³⁸⁴. If this acidification fails, degradation halts – even if autophagosomes fuse with lysosomes, their content won’t be fully digested. This point will become central in Nixon’s model. 2.2 Nixon’s Model – Autophagy Failure as a Cause of Alzheimer’s Pathology: Ralph Nixon’s research in the 2000s led to a paradigm wherein autophagy-lysosomal failure is not just a byproduct of neuron death but an active driver of it. The essence of Nixon’s model is captured in his recent 2024 review: “Autophagy failure, especially related to declining lysosomal (‘phagy’) functions, heightens the neuron’s vulnerability to factors underlying AD… In AD, an imbalance between heightened autophagy induction and diminished lysosomal function… yields an intracellular lysosomal build-up of undegraded substrates, including APP-βCTF… and Aβ peptide.”⁴⁵. Let’s break down this statement with evidence:

Autophagy Induction vs. Clearance Imbalance: In AD, neurons appear to overproduce

autophagosomes (perhaps due to stress like protein aggregation) but cannot clear them due to

lysosomal dysfunction¹⁴⁵. This was evidenced by findings like increased LC3-II (autophagosome marker) in AD brains or models, accumulation of AVs in dystrophic neurites³⁹¹⁴, and reduced cathepsin activity in those AVs. Boland et al. (2008) demonstrated in neuron cultures that if lysosomal function is blocked, autophagosomes accumulate rapidly⁵¹⁵² – mimicking what is seen in AD tissue, thus implicating a clearance block in AD. Nixon’s model posits that this autophagy flux block is an early event, not just terminal detritus. In mouse models carrying APP mutations, signs of autophagy build-up (like LC3-positive vesicles) appear before extracellular amyloid plaques⁵⁵⁸⁵. Nixon’s group showed that by 5 months of age, APP-transgenic mice had significant accumulations of partially acidified autophagic vacuoles in neurons, well ahead of plaque deposition at ~10–12 months⁵⁷⁸⁶.

Lysosomal Acidification Deficit: Perhaps Nixon’s single most important finding was linking familial AD mutations to lysosomal acidification problems. In 2010, Lee, Nixon et al. reported that Presenilin-1 (PS1) is essential for lysosome acidification⁴⁸⁴⁹. They showed that cells lacking

PS1, or expressing AD-mutant PS1, had autophagosomes that could not be digested due to failure

to acidify autolysosomes⁴⁸⁴⁹. Mechanistically, PS1 was found to help mature the glycosylation of the v-ATPase V0a1 subunit and ensure its proper trafficking to lysosomes⁸⁸⁷. Without functional PS1, v-ATPase subunits mislocalize, proton pumping is reduced, and lysosomal pH rises by ~0.5–1 unit, enough to inactivate acid hydrolases⁴⁸⁴⁹. This was a breakthrough: it connected the genetics of AD (PS1 mutations) with the cell biology of autophagy. It meant that in familial AD, every neuron is handicapped in its ability to degrade waste, from an early age, providing a fertile ground for protein accumulation. Further confirming this, PS1 mutant knock-in mice and fibroblasts from familial AD patients showed exactly these lysosomal defects⁸⁷⁵⁰. Subsequent work by other labs sometimes questioned parts of this (e.g., a 2011 study argued autophagy still occurs in PS1/PS2 knockout cells via alternate pathways⁶⁷), but by and large the lysosomal acidification deficit in PS1

mutants is well-supported⁸⁸⁸⁹. Notably, this provided a partial explanation for why amyloid

accumulates in AD: if autophagic clearance is impaired, the processing and turnover of APP and its fragments might be altered (indeed APP-βCTF, the direct precursor to Aβ, was found to accumulate in PS1-deficient cells⁸⁴⁹).

APP-βCTF as a Lysosomal “Poison”: Nixon’s recent work highlights an interesting vicious cycle. The β-carboxyl-terminal fragment of APP (βCTF or C99) itself can impair lysosomal acidification by binding to the v-ATPase and inhibiting it⁸³⁸⁴. Im et al. (2023) showed that phosphorylated APPβCTF (specifically at Y^682, part of the YENPTY motif) binds the V0a1 subunit of v-ATPase, preventing the V1 subcomplex from assembling, thus reducing proton pumping⁸³⁸⁴. In Down syndrome cells (which overproduce APP), lowering APP-βCTF levels or preventing its phosphorylation restored lysosomal acidity⁸⁴⁹⁰. They also found that AD model mice with high βCTF had reduced v-ATPase activity⁹⁰. This reveals a toxic feedback loop: initial lysosomal dysfunction (perhaps from PS1 mutation or aging) causes βCTF to accumulate; accumulated βCTF further inhibits lysosomes, causing more accumulation of βCTF and Aβ. Eventually, neurons become engorged with partially degraded material including βCTF and Aβ, contributing to what Nixon calls “PANTHOS” pathology ⁵⁹. The fact that APP-βCTF “blocks assembly of [the] vacuolar ATPase”⁹¹ underscores the idea that amyloidogenic processing and autophagy are intimately linked at the lysosomal level.
PANTHOS and Inside-Out Plaques: As touched on, PANTHOS (an acronym coined by Nixon meaning “poisonous flower” in Greek) describes neurons that have an extreme buildup of autolysosomal structures arranged like petals around the nucleus⁵⁸⁹². These neurons contain fibrillar Aβ aggregates inside those autophagic vesicles. Nixon’s team found that in five different AD mouse

models, neurons undergoing this PANTHOS process are the ones that ultimately give rise to extracellular plaques⁵⁹⁹³. By correlative microscopy, they showed PANTHOS-stage neurons

loaded with Aβ eventually lyse, and the remnants correspond to cored plaques⁵⁹⁹³. This is a profound shift in thinking: it implies that amyloid plaques may not be random extracellular aggregates but could be the efflux from exploded neurons that died because their autophagic/ lysosomal system collapsed. According to Nixon (2024), “β-amyloid accumulates intraneuronally in plaque-like aggregates that become extracellular senile plaques when these neurons die, reflecting an ‘inside-out’ origin of amyloid plaques.”⁵⁹. This concept directly echoes Fischer’s observation of plaques as a form of necrosis – except now we know what kind of necrosis: a specialized form of

lysosomal burst (lysosomal membrane permeabilization leading to cell death, also known as

lysosome-dependent cell death)⁹⁴¹⁰. Nixon identifies lysosomal membrane permeability (LMP) as the trigger for neuronal death in early AD, causing cathepsin enzymes to leak into the cytosol and initiate destruction of the cell from within⁹⁵¹⁰. In support, there is evidence of cathepsin B and other lysosomal enzymes being released in vulnerable neurons in AD models prior to cell death, and using drugs to stabilize lysosomal membranes can prevent neuron loss in some models¹⁰⁶⁹.

Evidence from Multiple Neurodegenerative Diseases: Nixon’s model doesn’t limit itself to AD. He

and others have noted similar autophagy-lysosomal pathologies in Parkinson’s disease (e.g., α- synuclein aggregating when lysosomal glucocerebrosidase is deficient) and in frontotemporal dementia (progranulin mutations cause lysosome problems). His 2024 review with Rubinsztein covers

Alzheimer disease, Parkinson disease and frontotemporal dementia; Huntington’s is not among them, and the four-disease version of the claim is an extension made elsewhere rather than a position that review takes. Huntington’s is often added to the list on the strength of cell and mouse work showing that mutant huntingtin impairs autophagosome cargo recognition (Martinez-Vicente et al. 2010) — though that study places the defect upstream of the lysosome and reports that the vacuoles are adequately eliminated by lysosomes, and staged human HD brain shows clearance preserved until advanced disease (Berg et al. 2025). For example, work in Parkinson’s models shows that the LRRK2 G2019S mutation causes modest lysosomal pH increase and reduces autophagic flux⁶⁵⁹⁶. Neurons with that mutation accumulate α-synuclein and have it cleared once LRRK2 activity is inhibited, consistent with restoration of lysosomal function⁶⁵⁹⁷. Similarly, Gaucher disease models (GBA1 mutation) demonstrate buildup of autophagic substrates and αsynuclein due to inefficient lysosomal digestion⁹⁸⁹⁹. Nixon often cites these parallels to argue

that lysosomal/autophagic dysfunction is a common denominator across many neurodegenerative

diseases³⁷⁵. This broadens the significance of his AD findings: it implies the ALP is a general “hub” for neurodegenerative processes. To illustrate Nixon’s model concretely, consider a neuron in an Alzheimer’s affected brain region (like the entorhinal cortex). According to the model: the neuron is under proteostatic stress (perhaps due to Aβ oligomers, tau misfolding, etc.) and upregulates autophagy (mTOR pathway inhibition, more autophagosomes form). Because of aging or an AD genetic mutation, this neuron’s lysosomes are not optimally acidic or efficient. So, while many autophagosomes form and try to digest cargo, they only partially succeed. The neuron begins accumulating large autophagolysosomal vesicles filled with partially digested material, including APP-CTFs, Aβ, possibly hyperphosphorylated tau (which can also be autophagy cargo). These vesicles clog up the neurites (hence the dystrophic neurites filled with dense bodies seen around plaques)⁴¹⁴⁴. The situation is akin to a garbage disposal that’s running but with a clogged drain – waste is being swept in but not flushed out. Over time, this unresolved autophagic stress triggers further problems: Lysosomes can become destabilized (maybe due to oxidative damage or the sheer burden). Lysosomal membranes then permeabilize, releasing enzymes like cathepsins into the cytosol. Cathepsins can degrade essential proteins and activate other death pathways (like calpain proteases and caspases)¹⁰⁰¹⁰. The neuron undergoes a form of lytic death – essentially digesting itself from inside (sometimes called autolytic cell death or lysosomal cell death). When the neuron bursts, it spills out its content, which includes those amyloid-laden vesicles and tangled tau. The amyloid aggregates coalesce in the extracellular space as a classical senile plaque with a dense core (the former intraneuronal deposits) and a halo of debris including remnants of dystrophic neurites and glial reactions. The tau that was once in tangles inside the cell now becomes extracellular ghost tangles or is taken up by glia. This sequence – autophagy failure → lysosomal leakage → neuron death → plaque formation – is the narrative Nixon’s model suggests, supported by the experimental pieces we’ve reviewed. 2.3 Key Experimental Milestones in Support of Nixon’s Model: It is worth highlighting a few milestone experiments in a timeline fashion to appreciate how the model gained traction:

2005: Nixon’s EM study shows massive autophagic vacuole accumulation in AD brains⁴¹¹⁴. This establishes autophagy impairment in human AD.
2008: Nixon’s group demonstrates pharmacologically or genetically boosting autophagy can sometimes reduce amyloid pathology in cell and animal models (e.g., rapamycin reduces Aβ in some models), indicating enhancing the clearance pathway can ameliorate disease features – a functional validation of the model that it’s beneficial to fix autophagy.
2010: Lee et al. in Cell⁴⁸⁴⁹ show PS1’s role in lysosome function, giving a genetic link. This also explains why autophagic vacuoles accumulate hugely in PS1-null cells: because they can’t acidify and degrade, just as observed.
2013: Nixon’s Eur J Neurosci review articulates “autophagy failure in AD due to defective lysosomal acidification” explicitly⁴⁷, indicating the field’s acceptance of this concept.
2015: Multiple studies by other labs show that Alzheimer mouse models have endolysosomal pathway gene expression changes, confirming that very early in disease the autophagy/lysosome genes are dysregulated (e.g., CLEAR network genes controlled by TFEB are altered).
2016-2019: Studies report that reducing expression of certain lysosomal proteins exacerbates AD pathology in mice, whereas increasing lysosomal biogenesis can attenuate it. For instance, overexpressing TFEB (a transcription factor that upregulates lysosome genes) in an AD model mouse led to more clearance of protein aggregates and improved cognitive function (Caccamo et al., 2016). This provides in vivo evidence that boosting the ALP is therapeutic, aligning with Nixon’s emphasis on lysosomal “tuning” as a target.
2022: Nixon’s lab and others show in vivo imaging of lysosomal pH and report the progression of acidification failure in AD mice⁵⁶¹⁰¹. They also connect intraneuronal Aβ accumulation with that failure, reinforcing cause-effect.
2024: Nixon’s Acta Neuropathologica review synthesizes all this and firmly states that lysosomal failure is a primary trigger of AD pathogenesis, not a late side-effect⁶⁹¹⁰². Additionally, he notes that in various major neurodegenerative disease models, preventing the lysosomal deficits significantly prevents neuron death and pathology⁶⁹¹⁰². This is a strong claim that aligns perfectly with our aim to unify upstream causes as converging on lysosomal collapse. In conclusion for this chapter, Ralph Nixon’s autophagy-lysosomal model provides a mechanistic explanation for many phenomena observed in Alzheimer’s disease: the presence of accumulated autophagic vacuoles, the intra-neuronal accumulation of amyloid and its eventual extracellular deposition, the link between familial AD genes and lysosome dysfunction, and the commonality of proteostatic stress across neurodegenerative diseases. The model effectively shifts the focus from “What protein is aggregating?” to “Why can’t the neuron clear the aggregating protein?”. It posits that the tipping point for neuronal survival is the integrity of the lysosomal system. As such, it sets the stage for our unifying theory: if multiple different factors (be they mutated proteins, environmental insults, or other stressors) can all impair the autophagy-lysosomal system, then they can all cause the same endpoint: “autophagic collapse” and neuronal death. This is what we will explore in the next chapter, examining those various factors in detail.

Chapter 3: Upstream Converging Factors – Genetic, Molecular, and Environmental Triggers of Autophagic Collapse

Having established the historical context (Fischer’s plaques) and the mechanistic model (Nixon’s autophagy-

lysosomal failure), we now focus on the diverse upstream events that can precipitate lysosomal

dysfunction and thereby neuronal death. The unifying hypothesis we advance is that seemingly disparate risk factors for neurodegenerative diseases all converge on lysosomal acidification failure and autophagy derailment. We will examine examples across genetics (e.g., PSEN1, APP mutations in AD; LRRK2, GBA1 in Parkinson’s), molecular interactions (APP-βCTF), and environmental factors (HSV-1 infection, possibly other microbes) and show how each ties into the autophagy-lysosomal pathway. 3.1 Familial Alzheimer’s Disease Genes – Presenilin-1 and APP: The most direct evidence for convergence comes from familial Alzheimer’s disease (FAD). Mutations in PSEN1 (and PSEN2) and APP cause early-onset AD. Initially, these were understood in the framework of the amyloid hypothesis: they increase production of aggregation-prone Aβ42 peptide, accelerating plaque deposition. However, as discussed, PSEN1 has a second, independent role in lysosomal function⁸⁵⁰. Presenilin-1 FAD mutations were shown to confer a loss-of-function phenotype regarding lysosomal acidification⁸⁵⁰. Cells from FAD patients with PSEN1 mutations show higher lysosomal pH, slower proteolysis of long-lived proteins, and accumulation of autophagic substrates⁴⁸⁴⁹. In mice partially lacking PS1, neurons failed to clear autophagosomes and exhibited neurodegeneration⁴⁸⁸⁷. These findings suggest that even if Aβ production is increased by PS1 mutations (a toxic gain-of-function in terms of amyloid), there is simultaneously a toxic loss-of-function in autophagy. The convergence is evident: PS1 mutations create a scenario where not only more waste (Aβ) is generated, but the waste disposal is broken. That double-hit results in exceptional buildup of junk inside neurons⁸⁵⁰. The APP gene itself, when duplicated (as in Down syndrome or APP gene duplication families) or mutated (e.g., the Swedish mutation increasing β-cleavage), provides another angle. Overexpression of APP leads to more APP-βCTF generation. As we saw, APP-βCTF is a potent inhibitor of v-ATPase when phosphorylated⁸³ ⁸⁴. In Down syndrome fibroblasts (with 3 copies of APP), high APP-βCTF levels correlate with impaired lysosomal acidification, and lowering APP-βCTF fixes the problem⁸⁴⁹⁰. Thus, APP overproduction (or inefficient processing) creates a feedback loop of lysosomal inhibition. This mechanism may underlie why people with Down syndrome (trisomy 21) develop early Alzheimer-like pathology: by their 30s and 40s, they often have ample amyloid plaques and tangles. The prevailing explanation has been simply “more APP, more Aβ”; but the autophagy view adds “more APP → more C99 fragment → lysosomal slowdown → more accumulation of all sorts of substrates (including Aβ and tau)”. Indeed, a recent study found that lysosomes in Down syndrome model mice are less acidic and less proteolytic, directly linking APP gene dose to autophagy impairment⁸³⁹⁰. Even sporadic AD might involve these pathways indirectly. Aging is associated with decline in lysosomal efficacy (possibly due to oxidized lipids, lipofuscin accumulation, etc.). Also, there’s evidence that APOE4, the strongest genetic risk factor for sporadic AD, may affect endosomal-lysosomal trafficking and lipid handling in ways that burden lysosomes. While APOE4’s mechanisms are complex, one hypothesis is that APOE4 leads to cholesterol-rich endosomes/lysosomes that disrupt normal function, indirectly causing autophagic stress (some studies have shown that APOE4 neurons have larger endosomes and potentially slower lysosomal clearance). This is another convergence: a genetic risk factor not obviously related to amyloid might still operate through the convergence point of organelle (lysosome) dysfunction. 3.2 Parkinson’s Disease Genes – LRRK2 and GBA1: We broaden the scope to Parkinson’s disease (PD), because it provides compelling examples of autophagy-lysosomal impairment as a unifying theme. PD is characterized pathologically by α-synuclein-rich Lewy bodies, but genetic discoveries show many PD genes are tied to lysosomal biology. Two prominent ones are LRRK2 and GBA1. LRRK2 (Leucine-Rich Repeat Kinase 2) is the most common familial PD gene. Mutations like G2019S cause a toxic gain-of-function in its kinase activity. Multiple lines of evidence connect LRRK2 to autophagy and lysosomal function¹⁰³¹⁰⁴. In neurons derived from LRRK2 mutant knock-in mice (G2019S), researchers observed decreased lysosomal acidity (~0.2 pH unit increase) and a reduction in basal autophagic flux¹⁰⁵ ⁶⁵. Schapansky et al. (2018) specifically reported that LRRK2 mutation “induces modest but significant changes in lysosomal morphology and acidification, and decreased basal autophagic flux”⁶⁵⁹⁶. They also found accumulation of insoluble α-synuclein in neurons with mutant LRRK2, which is exactly what one would predict if protein clearance is hampered⁶⁵⁹⁷. Notably, treating those neurons with a LRRK2 kinase inhibitor normalized lysosomal pH and autophagy and reduced α-syn buildup⁶⁵⁹⁷. This ties LRRK2’s pathogenic effect directly to lysosomal dysfunction. Mechanistically, LRRK2 is known to phosphorylate certain Rab GTPases that control vesicle trafficking; hyperactive LRRK2 may impair the trafficking/fusion of lysosomes or autophagosomes (some studies found LRRK2 overactivity stalls autophagosome maturation in axons)¹⁰⁴¹⁰⁶. Another angle is LRRK2’s effect on chaperone-mediated autophagy (CMA); mutant LRRK2 can block the assembly of the LAMP2A receptor, hindering CMA, which is one route for α-synuclein degradation¹⁰⁷. In sum, LRRK2 mutations create a scenario in PD analogous to PS1 in AD: an upstream kinase defect leads to downstream lysosomal failure, culminating in toxic protein accumulation (α-syn instead of Aβ, but the principle is the same). GBA1 (Glucocerebrosidase) mutations are the most frequent genetic risk factor for PD (and also cause Gaucher’s disease when homozygous). GBA1 encodes a lysosomal enzyme, glucocerebrosidase (GCase), which breaks down glucosylceramide. Heterozygous loss-of-function GBA1 mutations roughly five-fold increase PD risk. Why? When GCase is deficient, its substrates (glucosylceramide and related lipids) accumulate in lysosomes, potentially interfering with lysosomal function and also promoting α-synuclein aggregation (studies suggest glucosylceramide binds α-syn and stabilizes toxic oligomers). Pitcairn et al. (2019) and others have shown that GBA1-linked Parkinson’s features a shared phenotype of autophagiclysosomal dysfunction in both Gaucher patient iPSC-derived neurons and PD brains¹⁰⁸¹⁰⁹. Neurons with GBA1 mutations have enlarged, less efficient lysosomes and accumulate markers of incomplete autophagy (e.g., p62/SQSTM1, a protein normally degraded by autophagy, is elevated)¹¹⁰¹¹¹. There is also impairment of autophagic lysosome reformation (a recycling step after autophagy) noted in GBA1 mutant cells¹¹². Essentially, GBA1 mutation = lysosomal storage condition = secondary autophagy problem. The connection between GBA1 and LRRK2 is intriguing: some studies in dopaminergic neurons found that LRRK2 hyperactivity and GCase deficiency synergistically worsen lysosomal stress, whereas LRRK2 inhibition can partly rescue GCase trafficking to lysosomes. This again highlights convergence – different gene mutations in PD, both channeling into the lysosomal pathway. The result in PD is accumulation of αsynuclein and other substrates, leading to Lewy body formation and neuron death. Indeed, “protein aggregations… and canonical PD mutations converge on the lysosomal degradation system” as Mazzulli and colleagues put it¹⁰⁸, indicating dysregulated protein homeostasis via autophagy-lysosomal dysfunction mediates neurodegeneration in PD. 3.3 Environmental and Infectious Triggers – Herpes simplex virus type 1 (HSV-1) and others: Beyond genes, microbes and other environmental factors have been implicated in neurodegenerative disease. A provocative body of research, led by authors like Ruth Itzhaki and Judith Miklossy, argues that pathogens (especially viruses like HSV-1, and bacteria like spirochetes) might be causal or accelerative agents in Alzheimer’s disease¹¹³. One mechanism proposed is that these infections lead to chronic inflammation and direct damage; another, which aligns with our unifying theory, is that they disrupt autophagy, leading to protein accumulation. Herpes simplex virus type 1 (HSV-1) is a common virus that infects most people (cold sores), and it can reside latent in the peripheral nervous system. In APOE-ε4 carriers, Itzhaki’s group found HSV-1 DNA more frequently in AD brains⁶⁸. They proposed HSV1 in brain might promote amyloid/tangle formation and simultaneously block their clearance. In a 2008 article aptly subtitled “the autophagy connection,” Itzhaki et al. put forward that “HSV1 generates the main components of amyloid plaques and tangles… and by disrupting autophagy, it prevents degradation of these aberrant proteins, leading to their accumulation and deposition, and eventually to AD.”⁶⁸¹¹⁴. This statement is remarkably aligned with our convergence model: a virus both increases production of toxic proteins and inhibits autophagic clearance. What is the evidence for HSV1 inhibiting autophagy? Experimental cell culture studies show that HSV-1 infection can indeed sabotage the autophagy pathway. HSV-1 has evolved proteins to evade autophagic destruction – for instance, the viral ICP34.5 protein binds the autophagy protein Beclin-1 and inhibits autophagosome formation. Studies in neural cells confirmed that HSV-1 infection results in accumulation of autophagosomes that fail to fuse with lysosomes⁶³⁶⁴. One study found HSV-1 infection of neuronal-glial cultures led to intracellular accumulation of Aβ within autophagosomes that did not mature (essentially recreating an AD-like pathology in a dish)⁶³¹¹⁵. The autophagosomes containing Aβ failed to fuse with lysosomes in infected cells, indicating impaired degradation¹¹⁵. Another study reported that HSV-1 reduces the acidification of autolysosomes in glial cells¹¹⁶. Thus, HSV-1 introduces a roadblock in the ALP. If this occurs in brain during sporadic infections or reactivations, over years it could seed amyloid buildup and neuronal damage. Other pathogens have similar links: certain oral bacteria and spirochetes (like those causing Lyme disease or periodontal disease) have been found in AD brains, and Miklossy (2011, 2015) contends that chronic spirochetal infection causes “neurospirochetosis” that looks like AD, replete with plaques and tangles¹¹⁷ ¹¹³. How would spirochetes do this? They can trigger sustained inflammation and possibly release substances that hinder autophagy or directly contribute to amyloid deposition (some bacterial biofilms can be amyloidogenic). It’s beyond our scope to assess all pathogens, but crucial is the concept that chronic infection = chronic interferon/inflammation = autophagy inhibition. Interferon signaling and certain inflammatory pathways (like TNF, TGF-beta) can downregulate autophagic efficiency. Conversely, autophagy is known as a cell-autonomous defense against microbes, and many pathogens actively inhibit autophagy to survive. So from a convergence perspective, a chronic pathogen in the brain forces neurons into a compromised autophagic state, which then allows Alzheimer pathologies to flourish. Fischer’s analogy of plaques to “colonies of microorganisms”⁷ might have been more prescient than he realized: not that plaques are microbes, but microbes could be creating the conditions for plaques via autophagic collapse. 3.4 Other Factors – Traumatic Brain Injury, Aging, and Convergence: Two more upstream factors deserve mention: traumatic brain injury (TBI) and the simple fact of aging. TBI is an environmental risk for dementia; moderate/severe head injury increases AD risk by 2-4 fold. Mechanistically, TBI causes massive release of calcium in neurons, mitochondrial damage, and axonal injury – all triggers of autophagy. But studies have shown in experimental TBI that lysosomal rupture and cathepsin release occur, leading to Calpain-Cathepsin cascades that kill neurons (a process called “CALPNAIN” sometimes). Nixon’s 2024 paper notes that in various models, calcium-activated calpains contribute to lysosomal injury that induces leakage of cathepsins and additional death cascades¹⁰⁰¹⁰. TBI might then be seen as an acute inducer of Convergent Autophagic Collapse – the trauma over-activates autophagy and damages lysosomes (through mechanical disruption and calcium overload), leading to some neurons undergoing PANTHOS-like death. Indeed, autophagy inhibitors given after TBI can sometimes reduce cell loss, implying that runaway autophagy (or autophagy that can’t complete due to injury) is detrimental. Aging is the ultimate convergent factor: with age, cellular clearance systems gradually decline. Lysosomal membranes accumulate oxidative damage and lipofuscin (undigestible pigment) which raises pH and occupies capacity. Chaperone-mediated autophagy activity drops in aged neurons, proteasome activity declines, etc. This “garbage catastrophe” hypothesis of aging dovetails with our theory – in essence, aging itself is an upstream event that weakens autophagy-lysosomal efficiency to the point where proteins that wouldn’t accumulate in youth begin to, and eventually tip into pathology. This explains why even in absence of familial mutations or infections, sporadic late-onset neurodegeneration can happen. It’s simply the slow convergence to autophagic collapse through accumulation of minor insults and wear-and-tear. Supporting this, nearly all late-onset neurodegenerative diseases feature evidence of endolysosomal dysfunction when carefully examined, and interventions that “rejuvenate” lysosomes (like overexpressing TFEB or giving small molecule activators of lysosomal biogenesis) improve tissue health in aged animals¹⁰⁸¹¹⁸. 3.5 Synthesis – Common Pathway of Lysosomal Acidification Failure: Now, synthesizing these examples: whether the initiating event is a mutation in a membrane protein (PSEN1, APP), a kinase hyperactivity (LRRK2), a lysosomal enzyme deficiency (GBA1), or an infectious/inflammatory insult (HSV1), the downstream effect in neurons often includes impaired lysosomal acidification/proteolysis and autophagic flux reduction. The cell, unable to degrade cargo, accumulates potentially toxic substrates (be it Aβ, α-syn, or others). These substrates can themselves further inhibit lysosomes (Aβ can destabilize membranes, α-syn can block protein import into lysosomes in CMA, etc.), reinforcing the dysfunction. Eventually, the threshold is crossed where either the neuron undergoes apoptosis due to proteotoxic stress or, as Nixon emphasizes, lysosomal membrane permeabilization triggers a cascade of cathepsin-mediated cell death⁹⁵¹⁰. This scenario is consistent with what pathologists see in advanced disease: “granulovacuolar degeneration” in AD neurons (little vacuoles in cytoplasm – possibly residual autophagic vacuoles), “marine bodies” in PD (pale bodies reflecting lysosomal aggregates), and so on. It’s the morphological imprint of autophagic congestion. Additionally, glial cells (microglia) eventually come to clear the mess after neuronal death, but if the death is too widespread or repeated, chronic neuroinflammation sets in, compounding problems (microglia themselves can spread pathology by excreting pro-inflammatory factors, etc.). However, microglial invasion tends to happen relatively late in this model – interestingly, in PANTHOS neurons in mice, microglia did not immediately attack them while they were alive with accumulated Aβ, only after they died⁵⁴. This suggests the neuron can be dysfunctional for a long time (with autophagic buildup) before the final collapse. That window might be the therapeutic opportunity: we could try to restore lysosomal function in those neurons to prevent death. In conclusion of this chapter, we have illustrated with concrete examples how very different triggers of

clearance leading to intracellular accumulation of toxic species and ultimately neuronal demise. This not only strengthens the plausibility of our unifying theory but also underscores a critical point: treatments targeting the autophagy-lysosomal pathway could have broad efficacy across diseases, irrespective of the initial trigger. For example, a drug that enhances lysosomal acidification (some studies are looking at histone deacetylase 6 inhibitors which promote v-ATPase assembly¹¹⁹, or small molecules that stabilize lysosomal membranes) might help familial AD patients with PS1 mutations, sporadic AD patients, and even Parkinson’s patients with LRRK2 mutations alike. Having laid out the evidence for convergence, we now formally propose in the next chapter our unifying theory, “Convergent Autophagic Collapse,” integrating Fischer’s early pathological concepts with Nixon’s mechanistic framework, and discuss how this theory can explain the observations of both pioneers in one cohesive model.

Chapter 4: Convergent Autophagic Collapse – A Unifying Theory of Neurodegenerative Neuronal Death

In this chapter, we synthesize the insights from previous chapters to propose the unifying theory termed Convergent Autophagic Collapse. This theory posits that diverse etiological factors in neurodegenerative diseases ultimately converge on a critical cellular event: the collapse of the autophagy-lysosomal system, particularly due to lysosomal acidification failure, leading to neuronal death and the hallmark pathologies of diseases like Alzheimer’s and Parkinson’s. We will articulate the elements of this theory, demonstrate how it encompasses Fischer’s and Nixon’s findings, and explore its explanatory power and implications. 4.1 Defining Convergent Autophagic Collapse: The theory can be summarized as follows:

Multiple upstream factors (genetic mutations, protein misfolding, metabolic or oxidative stress, infections, trauma, aging) converge on the autophagy-lysosomal pathway (ALP), causing a critical level of dysfunction.
A tipping point is reached when lysosomal function – in particular, the ability to acidify and degrade cargo – is sufficiently impaired. At this point, autophagic flux is effectively stalled: autophagosomes and undigested substrates accumulate, and normal cellular homeostasis breaks down.
This state is termed “Autophagic Collapse.” It is characterized morphologically by a neuron engorged with autophagic vacuoles (AVs), functionally by a near-total loss of proteolytic capacity, and clinically by an irreversible trajectory toward cell death. Autophagic collapse corresponds to what Nixon describes as the extreme autophagy pathology in AD (PANTHOS neurons)¹⁰⁰¹⁰ and what Fischer saw as neurons with “coarse fibrillary degeneration” surrounded by plaque material¹¹⁷².
Once a neuron undergoes autophagic collapse, cell death ensues via lysosome-dependent

mechanisms. Lysosomal membrane permeabilization (LMP) releases cathepsins that trigger

degenerative cascades¹⁰⁰¹⁰. The neuron might undergo a form of calpain/cathepsin-mediated necrosis or apoptosis (sometimes called “autophagic cell death” in older literature, though that term can be misleading).

The death of the neuron, in the presence of accumulated undegraded proteins, gives rise to the extracellular lesions characteristic of the disease. In AD, the bursting neuron releases amyloidladen vesicles and tau, forming an amyloid plaque and contributing to extracellular tangle material ⁵⁹. In PD, the death of a dopaminergic neuron releases α-synuclein aggregates which may be taken up by other cells or remain as Lewy bodies/neurites in the neuropil.
This process is “convergent” because regardless of whether the initial cause was excess protein production (APP mutation), impaired degradation machinery (PSEN1, GBA1), or external toxins (viruses, TBI), the final pathway of cell destruction is the same: via failure of the autophagylysosomal system.
The theory further implies an “inside-out” nature to pathology progression⁵⁹, aligning with Nixon’s view that plaques form from inside neurons and with Fischer’s notion of plaques as necrotic foci¹²⁷¹. It suggests the primary locus of pathogenesis is within the neuron (intraneuronal autophagic stress), with extracellular pathology being secondary. In essence, Convergent Autophagic Collapse merges the two narratives we’ve traced: Fischer’s pathological observations of neuron-associated lesions and Nixon’s mechanistic understanding of autophagy failure. It asserts that Fischer’s “miliary necrosis” is actually the histological footprint of autophagic collapse – a dying neuron’s debris field. Thus, what Fischer described qualitatively, this theory describes quantitatively and mechanistically. 4.2 How the Theory Explains Fischer’s and Nixon’s Findings: Let’s explicitly map Fischer’s early 1900s findings and Nixon’s 2000s findings onto this theory:
Fischer observed: Plaques (miliary necroses) consisting of a central core and radiating fibrils, often near dying or damaged neurons; Tangles (coarse fibrillary material) inside neurons in some cases; and a progression in size/number of plaques over time¹¹⁷². He thought these could represent degenerative products of neurons and possibly involve an infectious process²³⁸⁰.
Explanation by Convergent Autophagic Collapse: Plaques are indeed degenerative products of neurons – specifically, the remnants of neurons that underwent autophagic collapse and died. The central amyloid core corresponds to aggregated undegraded protein (Aβ) that was inside the neuron’s autolysosomes⁵⁸¹²⁰. The radiating fibrils and “bulbous axonal terminals” Fischer drew²⁰²¹ correspond to dystrophic neurites filled with autophagic debris that surrounded the neuron pre-

death³⁹⁴⁴. The theory explains the continuum (stages I–V) Fischer described: early “star”

plaques are neurons in early autophagic stress (some buildup but neuron intact), whereas large “druse” plaques are end-stage where the neuron has just lysed, leaving a lump of amyloid (homogeneous core) with entangled neuritic debris¹⁸⁷⁷. The co-occurrence of tangles in some plaque-bearing neurons is explained by tau being another substrate that accumulates when proteostasis fails. Tau, normally turned over partly via autophagy, hyperphosphorylates and forms tangles when autophagy/proteasome are overwhelmed. So tangles and plaques together mark neurons that were in collapse (tau aggregating inside, amyloid aggregating inside).

Fischer’s hint at infection finds a place too: Convergent Autophagic Collapse doesn’t require infection, but is perfectly compatible with infection as one trigger. If Fischer’s “germ” were TB or syphilis (which he and others suspected analogies to), the theory would say: such chronic infections in brain cause neuronal autophagic stress (through inflammation or direct microbial action), thereby initiating the collapse cascade. In fact, PANTHOS has been observed to some degree in neurosyphilis brains in historical literature (old pathologists noted similarities between general paresis and senile plaques¹²¹¹²²).
Nixon observed: Autophagic vacuole accumulation in neurons, lysosomal acidification defects, intraneuronal Aβ accumulation (PANTHOS), and lysosomal leakage causing neuron death with extrusion of plaques⁵⁹. He also observed that fixing lysosomal defects can prevent pathology in models⁶⁹¹⁰².
Explanation by Convergent Autophagic Collapse: This is essentially the mechanistic core of the theory. Nixon’s findings provide the causal chain: autophagy induction + lysosomal failure = autophagic buildup = PANTHOS = cell death (collapse) = plaque. The theory fully incorporates this. It even extends it by positioning various triggers upstream of Nixon’s identified mechanisms. For instance, Nixon notes APP-βCTF inhibits v-ATPase⁵⁸²; our theory folds that into a larger set of factors that inhibit v-ATPase (like PS1 mutations or even environmental pH disruptors).
Moreover, the theory accounts for why therapies that help lysosomal function show promise: because they counteract the collapse process. In a sense, the unifying theory elevates lysosomal acidification to a final common denominator – any therapy or insult that modulates it will have broad consequences. This matches Nixon’s view that lysosomal deficits are prime therapeutic targets⁶⁹ ¹⁰². It also resonates with historical wisdom: in the pre-amyloid era, pathologists called AD a “primary degenerative dementia,” implying something inherently wrong with neuron maintenance. Convergent Autophagic Collapse nails down what that something is – the failure of self-cleaning. 4.3 Diagramming the Unified Mechanism (Conceptual Model): Imagine a flow chart or network diagram: Multiple arrows from different boxes (PSEN1 mutation, APP mutation, APOE4, HSV-1 infection, TBI, aging) all funnel into one box labeled “Lysosomal Acidification ↓ / Autophagic Flux Impairment”. From that box, an arrow leads to “Undegraded substrates accumulate (Aβ, tau, α-syn, etc.)”. Feedback arrows go from accumulated substrates back to worsen lysosomal function (e.g., Aβ and APP-CTF further raising pH, α-syn inhibiting CMA). Eventually, this feed-forward loop is unsustainable, leading to “Lysosomal Membrane Permeabilization & Cathepsin Release”. That causes “Neuronal Death”. And neuronal death, in presence of accumulated proteins, results in “Extracellular aggregate deposition (plaques, Lewy bodies, etc.)”. Glial cells react and clean up some debris, but might also acquire some aggregates (leading to spreading of pathology). This whole sequence constitutes Convergent Autophagic Collapse. Notably, the theory provides a unifying explanation for both major pathologies in AD: plaques (amyloid) and tangles (tau). Both are seen as byproducts of autophagic collapse – amyloid from failed lysosomal digestion of APP fragments⁵⁹, tau tangles from failed proteasomal/autophagic turnover of tau plus calciummediated kinases that hyperphosphorylate tau during stress. It diverges from the notion that one (amyloid) is the upstream cause of the other (tau). Instead, both can arise in parallel from a common upstream cellular failure. This could clarify why tau correlates better with cognitive decline than amyloid: tau tangles might reflect a more advanced stage of collapse (intracellular catastrophe) whereas amyloid can accumulate even when the neuron is struggling but not yet dead. In the theory, amyloid buildup begins earlier (moderate autophagy failure), tangles a bit later (when proteostasis is severely disturbed), which aligns with Braak staging – amyloid changes precede tau changes widely. 4.4 Scope Beyond AD – and Where the Framework Stops: While we have mostly framed this around Alzheimer’s (due to Fischer’s context) and touched on Parkinson’s, Convergent Autophagic Collapse could be a broader neurodegenerative paradigm. A framework of this kind is only worth having if it also says where it does not apply, so the survey below distinguishes the diseases whose causal genes encode parts of the clearance apparatus — where the claim is at its strongest — from those where they do not. Consider other diseases: - Frontotemporal dementia (FTD): Some forms are caused by progranulin mutations – progranulin haploinsufficiency leads to impaired lysosome function because progranulin is a lysosomal protein. Sure enough, FTD patients with progranulin mutations have lower cathepsin activity and accumulate lipofuscin (A form of autophagy failure sign). They also get TDP-43 protein aggregates, which could result from impaired clearance. This fits the model. - ALS (Amyotrophic Lateral Sclerosis): C9ORF72 expansions cause ALS/FTD, and C9ORF72 protein is involved in endosomal trafficking; its loss might hamper autophagy initiation. Many ALS-linked proteins (TBK1, SQSTM1, VCP) are autophagy related. So ALS could be convergence on autophagy too, albeit manifesting differently (motor neurons not long-living enough to form amyloid plaques, but they die via proteostasis failure). - Huntington’s disease: This is where the framework stops. The causal gene encodes no part of the clearance apparatus, and the pathway turns out to be competent for most of the illness. In HD cell and mouse models, mutant huntingtin impairs autophagosome cargo recognition — a defect upstream of the lysosome, in a system whose vacuoles those models report as adequately eliminated by lysosomes (Martinez-Vicente et al. 2010). In staged human HD brain, neurons are comparatively normal at Vonsattel grade HD2; cargo-loaded autophagosomes and cathepsin-positive autolysosomes are readily observed, implying no significant blockage of autophagosome formation or of autophagosome–lysosome fusion; and upregulated lysosomal biogenesis with preserved proteolysis maintains clearance through early disease, with huntingtin build-up and autolysosome accumulation appearing only at advanced stages, more in striatum than cortex (Berg et al. 2025). Clearance failure in HD is therefore late and consequential rather than early and causal. The practical corollary runs the other way from Alzheimer’s: because the machinery is fully competent early, that is the window in which stimulating it can be expected to work, whereas in AD induction is already raised and the deficit lies downstream in degradative capacity. - Prion diseases: Misfolded prion protein is hard to clear, and prion-infected neurons show massive lysosomal dilation (due to accumulating indigestible PrPsc aggregates), culminating in spongiform change (holes where neurons died). That again can be cast as autophagic stress (cells trying to eat prions, failing, then dying). Thus, Convergent Autophagic Collapse provides a lens to see commonality in what used to be siloed diseases. It doesn’t mean all diseases look identical – the specific protein that accumulates differs (Aβ in AD, α-syn in PD, etc.), likely dictated by which proteins are most aggregation-prone and abundant in those cell types. Where the genes that cause a disease encode parts of the clearance apparatus, why those proteins accumulate at all may share the answer: autophagy-lysosomal collapse. Where they do not, as in Huntington’s, the same picture in end-stage tissue records the arrival of the collapse rather than its origin, and the lens should be held more loosely. 4.5 Implications and Testable Predictions: A good theory yields predictions. For instance, this theory predicts: - Enhancing lysosomal acidification or protease activity should slow or prevent neurodegeneration across multiple disease models. There is evidence for this: e.g., overexpressing v-ATPase subunits or treating with drugs that lower lysosomal pH (within reason) might reduce pathology. One study found that activating TFEB (master regulator of lysosomal biogenesis) in an AD mouse reduced amyloid and tau pathology and improved cognition, which is consistent with our theory that improving clearance counters disease¹⁰⁸¹⁰⁹. - Conversely, inducing lysosomal dysfunction in a healthy animal should be sufficient to produce neurodegenerative changes. There are partial proofs: mice lacking cathepsin D (a lysosomal enzyme) develop an LSD with some neurodegeneration; inhibitors of v-ATPase given to mice cause neuron death. A provocative experiment would be neuron-specific knockdown of Presenilin-1’s lysosomal function (but not its γ-secretase function) – our theory would predict that even without Aβ overproduction, those mice might develop inclusion bodies and neurodegeneration due to autophagic build-up. - The theory also predicts a correlation between markers of autophagy collapse and disease progression in humans. Indeed, CSF or PET markers of lysosomal function might correlate with cognitive decline better than amyloid. Some studies show that levels of lysosomal enzymes in CSF (like cathepsin B, L, or even the ratio of LC3-II/LC3-I) correlate with AD severity. - A very direct prediction: if Convergent Autophagic Collapse is the final common pathway, then removing the specific aggregating protein (like Aβ or α-syn) without fixing autophagy might not save the neuron. This could explain why some amyloid-clearing therapies didn’t show big cognitive benefits – if the neuron was already in collapse, removing amyloid from outside won’t resurrect it. Our theory thus suggests combination therapies: clear the aggregates and restore lysosomal function to actually help neurons recover. 4.6 Bridging Historical and Modern Perspectives: Finally, it’s worth highlighting how this theory brings Fischer and Nixon into the same frame: - Fischer provided the phenotype of autophagic collapse (the anatomical changes), calling attention to their importance. - Nixon uncovered the genotype or pathway of collapse (the molecular interactions and events leading to it). - The Convergent Autophagic Collapse theory explicitly credits both: we wouldn’t have known what we were looking for without Fischer’s plaques and tangles descriptions, and we wouldn’t know how it happened without Nixon’s ALP research. This unified theory also reframes AD as not just “protein aggregation disorder” (the amyloid/tau dualism) but as a protein clearance disorder. This aligns with an emerging consensus in the field that the proteostasis network is central to these diseases. It also resonates with what many neuropathologists have observed: e.g., the presence of granulovacuolar degeneration (GVD) bodies in AD neurons, which are small autophagic vesicles often found near tangles. GVD is often seen as a sign of failed autophagy. Convergent Autophagic Collapse neatly includes GVD as part of the collapse process (they’re perhaps earlier stage evidence of autophagy stress). To conclude this chapter, the Convergent Autophagic Collapse theory provides a robust, integrative framework for understanding neurodegenerative disease cause and progression. It validates and builds upon Oskar Fischer’s early 20th-century vision of dementia as a disease of “fibrillar degeneration” and Ralph Nixon’s 21st-century vision of dementia as a disease of “autophagy failure.” In doing so, it closes a centurywide loop in the history of neuroscience: what began with silver-stained plaques in a Prague histology lab now culminates in molecular pathways and targets in cutting-edge labs, yet the story they tell is one and the same. In the concluding section, we will reflect on the broader significance of this synthesis and the future directions it suggests for research and therapy.

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.

Each claim below carries a tier and, where it is not settled, the observation that would settle it. 5 claims · 4 not yet settled

Strong (imported, established) — Cellular waste disposal is essential to neuronal survival, and its failure is documented across dementias.

The molecular half of the paper's 'full circle' and the better evidenced of the two.

Moderate (inference, the paper's own claim) — Where the genes that cause a disease encode parts of the clearance apparatus, clearance breakdown is the common road: the endosomal arm of Alzheimer's, progranulin-deficient frontotemporal dementia, GBA1-associated Parkinson's.

The defensible form of the convergence thesis. Human genetics places the lesion inside the pathway, which is a stronger position than finding the pathway disturbed in end-stage tissue. Convergence arguments otherwise gain their appeal from coverage, and coverage is not demonstration: a pathway implicated everywhere may be a common consequence rather than a common cause.

What would settle it. An etiology of this kind shown to produce the disease phenotype without passing through clearance failure, which would bound the convergence.

Weak (human tissue, against the claim) — All roads lead to the same failure — every etiology of dementia and related neurodegeneration converges on clearance breakdown, Huntington's included.

The strongest form of the master claim, and it is already bounded. Staged human Huntington's brain shows cargo-loaded autophagosomes, cathepsin-positive autolysosomes, upregulated lysosomal biogenesis and preserved proteolysis through early disease, with substrate accumulating only at advanced stages. The founding cell-model study places the Huntington's defect at cargo recognition, upstream of the lysosome, and reports the vacuoles adequately eliminated. The review the convergence leans on names Alzheimer's, Parkinson's and frontotemporal dementia, not Huntington's.

What would refute it. Already bounded by that evidence. What survives is that clearance is overtaken late in Huntington's, as a consequence of a lesion that begins elsewhere.

Weak (imported, non-specific) — Autophagic capacity declines with age in every neuron, which is why these diseases are diseases of late life.

True and universal, and for that reason close to uninformative. A decline shared by everyone who ages cannot by itself explain who develops which disease, or when, and it is a separate claim from the causal ones above.

Weak (predicted, untested) — The convergence yields actionable insight — a single point of intervention effective across etiologies.

The practical payoff of a master theory, and the part that has not been demonstrated. Convergence can be real and still leave the bottleneck undruggable. The Huntington's evidence adds a further problem for the single-intervention form: there the intervention must be applied early, while the machinery still works, which is the opposite of the timing the Alzheimer's case implies.

Conclusion

In this dissertation, we journeyed from the early 1900s microscopes of Oskar Fischer to the modern molecular assays of Ralph Nixon, uncovering a coherent narrative that links them. We have shown that Fischer’s detailed histopathological findings—his “miliary necroses” (senile plaques) and “fibrillary proliferations” (neurofibrillary tangles) in the brains of dementia patients—can be reinterpreted through the lens of Nixon’s autophagy-lysosomal model as evidence of neurons overwhelmed by proteostatic stress and failing in their self-clearance mechanisms. Through a rigorous literature review and comparative analysis, we proposed the unified theory of Convergent Autophagic Collapse, which holds that a breakdown in the autophagy-lysosomal pathway is the final common pathway leading to neurodegenerative disease, integrating genetic, environmental, and aging-related factors into one pathogenic process. This work has several implications for both the history of science and molecular neuroscience. Historically, it rehabilitates and illuminates Oskar Fischer’s legacy. Fischer emerges not as “Alzheimer’s rival” in a narrow sense, but as a pioneer who essentially documented the phenomenon of autophagic collapse without the means to name it as such. He meticulously catalogued how neurons and their surroundings degenerated in senile dementia, emphasizing plaques’ importance²⁹ and even suspecting an infectious or “foreign” element²³. Our synthesis suggests Fischer was observing the end-stage of a process we now understand at the cellular level. By connecting Fischer to Nixon, we demonstrate that current science, rather than rendering early observations obsolete, actually validates and contextualizes them. This is a powerful message in the history of neuropathology: that careful morphologic observation can presage mechanisms discovered decades later. In peer-reviewed defenses and academic discourse, acknowledging Fischer’s contributions provides a richer narrative of AD’s discovery, one that corrects the historical record to include the breadth of early 20th-century research³⁰. It also shows how scientific ideas can be lost and found: Fischer’s idea of a “germ” causing plaques lay dormant, but today the microbial hypothesis of AD is actively investigated, and intriguingly, through an autophagy perspective that Fischer would likely appreciate⁶⁸. For molecular neuroscience and the field of neurodegeneration, the Convergent Autophagic Collapse theory calls for a paradigm shift in how we conceptualize these diseases. It suggests that instead of siloing diseases by the specific protein that aggregates (amyloid, tau, α-synuclein, TDP-43, etc.), we focus on the shared defect in the cellular housekeeping system. That suggestion is at its strongest where the genes that cause the disease encode parts of that system — the endosomal arm of Alzheimer’s through APP, PSEN1 and SORL1; progranulin-deficient frontotemporal dementia; GBA1-associated Parkinson’s — and it weakens as one moves away from them. This doesn’t diminish the importance of those proteins, but it frames them as symptoms as much as causes. Thus, therapies should not only aim to remove pathological aggregates (e.g., amyloid plaques via immunotherapy) but also to bolster the cell’s own clearance and survival mechanisms. In practical terms, this could mean developing drugs that stabilize lysosomal pH, enhance v-ATPase assembly, activate lysosomal biogenesis (e.g., TFEB activators), or prevent lysosomal membrane permeabilization. Already, some preclinical studies are testing small molecules along these lines (for example, modulating calcium channels to reduce lysosomal leak, or repurposing drugs for lysosomal storage diseases in AD models). Our theory provides a strong rationale for such approaches: if you can prevent the “collapse,” the neuron might live on even in the face of pathogenic insults. Another salient insight from our work is the “inside-out” perspective of lesion formation⁵⁹. This perspective urges researchers to monitor intraneuronal changes closely, rather than focusing only on extracellular plaques/tangles or overall brain atrophy. It aligns with clinical observations that subtle cognitive impairment begins long before massive extracellular pathology is visible via imaging – likely when neurons are entering the collapse phase internally. This means diagnostic strategies could evolve to detect signs of autophagic stress in patients early (perhaps via CSF markers of lysosomal enzymes, PET ligands for autophagy activity, or blood biomarkers related to endosomal uptake). As research advances, one could imagine a future where a panel of biomarkers indicating lysosomal stress flags individuals at risk of neurodegeneration before irreversible loss has occurred, allowing early intervention. By unifying multiple upstream factors, the theory also fosters a more inclusive research ethos: it shows that those studying Alzheimer’s (amyloid/tau), Parkinson’s (α-synuclein), ALS (TDP-43) and frontotemporal dementia are often examining different facets of one problem, and it shows where that is not so — Huntington’s researchers are examining a disease that reaches the clearance pathway late and from outside it. This might encourage cross-disease collaborations and cross-fertilization of therapeutic ideas, provided the transfers respect the timing. For instance, drugs being tried in lysosomal storage disorders or in Parkinson’s (like Ambroxol, which boosts GCase activity) could be tested in Alzheimer’s¹⁰⁸¹⁰⁹. But the principle that enhancing lysosomal function is universally beneficial should not be stated that broadly: the Huntington’s evidence says such an intervention needs to arrive early, while the machinery still works, which is the opposite of the timing that the Alzheimer’s case implies (Berg et al. 2025). Our proposed theory is admittedly a broad framework, and like any, it has its challenges and avenues for refinement. One challenge is determining thresholds: how much lysosomal impairment is needed to trigger collapse? Why do some neurons (e.g., in hippocampus or substantia nigra) succumb earlier than others? The theory would suggest it’s either because they face higher burden (e.g., metabolic load, more prone to protein aggregation) or inherently have lower autophagic capacity (some evidence indicates different neuron types have different basal autophagy levels). These nuances require further research. Additionally, not all aspects of neurodegeneration may tie neatly into autophagy – for example, vascular contributions (small strokes, blood-brain barrier leaks) also cause dementia. However, even vascular issues might interface with autophagy (ischemia can cause calpain activation and lysosomal rupture). Thus, in future expansions of the theory, we might incorporate how systemic factors (vascular health, systemic inflammation) feed into neuronal autophagic health. In concluding, we emphasize that Convergent Autophagic Collapse is more than a theoretical abstraction; it’s a convergence of historical and contemporary knowledge that yields actionable insights. It vindicates early 20th-century neuropathological wisdom that the “waste” observed in brains of dementia patients holds the key to their illness, and it corroborates early 21st-century molecular wisdom that cellular waste disposal is crucial for neuron survival. This convergence represents a kind of full-circle moment in the field. Just as Fischer and his contemporaries united around the idea that plaques were central to dementia (even if they debated cause), we foresee the field uniting around the idea that autophagy-lysosomal dysfunction is central to neurodegeneration (with ongoing debates only about what triggers it in each case). In a poetic sense, one might say that the “mysterious little Alzheimer’s germ” Fischer pondered¹²³ was not a bacterium after all, but the cell’s own failing lysosomes – a seed of destruction from within. Our job as researchers and clinicians is now to recognize this and translate it into interventions: to prevent that germ from taking hold by fortifying the neuron’s clearing system. The story of neurodegeneration, from Fischer to Nixon, teaches us that to defeat these diseases, we must treat not just the visible lesions but the invisible process that creates them. By incorporating a century of insights, the theory of Convergent Autophagic Collapse provides a roadmap to do exactly that, opening new chapters in both the science and history of understanding Alzheimer’s and related neurodegenerative disorders.

References (Chicago Style)

Alzheimer, Alois. 1911. “Über eigenartige Krankheitsfälle des späteren Alters (On Certain Peculiar Cases of Old Age Disease).” Zeitschrift für die gesamte Neurologie und Psychiatrie 4: 356–385. (English translation in Bick et al., The Early Story of Alzheimer’s Disease, 1987).
Berg, Martin J., Veeranna, Corrinne M. Rosa, Asok Kumar, Panaiyur S. Mohan, Philip Stavrides, Sandipkumar Darji, Deanna M. Marchionini, Dun-Sheng Yang, and Ralph A. Nixon. 2025. “Pathobiology of the Autophagy-Lysosomal Pathway in the Huntington’s Disease Brain.” Acta Neuropathologica Communications 13 (1): 228. DOI 10.1186/s40478-025-02131-8">https://doi.org/10.1186/s40478-025-02131-8.
Boland, Benedict, et al. 2008. “Autophagy Induction and Autophagosome Clearance in Neurons: Relationship to Autophagic Pathology in Alzheimer’s Disease.” Journal of Neuroscience 28 (27): 6926– 6937⁵¹⁵².
Cataldo, Anne M., and Ralph A. Nixon. 1990s. [Series of studies on endosomal-lysosomal alterations in Alzheimer’s disease; e.g.,] 1996. “Lysosomal System Proteins as Markers of the Progression of Alzheimer’s Disease: Analysis of Stages I–IV.” Neurobiology of Aging 17 (4): 593–Pulished.
Find this paper
Engelhardt, Eliasz. 2023. “Oskar Fischer and the drusiform necrosis.” Revista Brasileira de Neurologia 59 (3): 30¹¹⁷².
Im, Eunju, et al. 2023. “Lysosomal Dysfunction in Down Syndrome and Alzheimer Mouse Models Is Caused by v-ATPase Inhibition by Tyr^682^-Phosphorylated APP-βCTF.” Science Advances 9 (30): eadg1925⁸³⁸⁴.
Itzhaki, Ruth F., S. L. Cosby, and M. A. Wozniak. 2008. “Herpes Simplex Virus Type 1 and Alzheimer’s Disease: The Autophagy Connection.” Journal of NeuroVirology 14 (1): 1–4⁶⁸.
Find this paper
Lee, Ju-Hyun, et al. 2010. “Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations.” Cell 141 (7): 1146–1158⁴⁸⁴⁹.
Martinez-Vicente, Marta, Zsolt Talloczy, Esther Wong, Guomei Tang, Hiroshi Koga, Susmita Kaushik, Rosa de Vries, Esperanza Arias, Spike Harris, David Sulzer, and Ana Maria Cuervo. 2010. “Cargo Recognition Failure Is Responsible for Inefficient Autophagy in Huntington’s Disease.” Nature Neuroscience 13 (5): 567–576. DOI 10.1038/nn.2528">https://doi.org/10.1038/nn.2528.
Miklossy, Judith. 2015. “Historic Evidence to Support a Causal Relationship Between Spirochetal Infections and Alzheimer’s Disease.” Frontiers in Aging Neuroscience 7: 46⁷⁸¹.
Nixon, Ralph A., et al. 2005. “Extensive Involvement of Autophagy in Alzheimer Disease: An ImmunoElectron Microscopy Study.” Journal of Neuropathology & Experimental Neurology 64 (2): 113–122⁴¹ ¹⁴.
Find this paper
Nixon, Ralph A. 2013. “Autophagy, Amyloidogenesis and Alzheimer Disease.” Journal of Cell Science 126 (Pt 14): 2931–2942. (Also Nixon, R.A. 2013. “Autophagy failure in Alzheimer’s disease and the role of defective lysosomal acidification.” European Journal of Neuroscience 37: 1949–1961)⁴⁷.
Find this paper
Nixon, Ralph A. 2024. “Autophagy-Lysosomal-Associated Neuronal Death in Neurodegenerative Disease.” Acta Neuropathologica 148 (1): 42 (review)⁵¹⁰.
Find this paper
Pitcairn, Caleb, Willayat Y. Wani, and Joseph R. Mazzulli. 2019. “Dysregulation of the AutophagicLysosomal Pathway in Gaucher’s Disease and Parkinson’s Disease.” Neurobiology of Disease 122: 72– 82¹²⁴¹⁰⁹.
Find this paper
Schapansky, Jason, et al. 2018. “Familial Knockin Mutation of LRRK2 Causes Lysosomal Dysfunction and Accumulation of Endogenous Insoluble α-Synuclein in Neurons.” Neurobiology of Disease 111: 26–35⁶⁵⁹⁶.
Wozniak, Matthew A., et al. 2009. “Herpes Simplex Virus Type 1 DNA Is Located Within Alzheimer’s Disease Amyloid Plaques.” Journal of Pathology 217 (1): 131–138. (Supporting the presence of HSV1 in plaques).
Find this paper
Primary Sources by Oskar Fischer:

Fischer, Oskar. Benezit Dictionary of Artists 2011. DOI 10.1093/benz/9780199773787.article.b00064733.

(Note: All inline citations 【source†lines】 correspond to specific supporting excerpts from the connected references above, illustrating key points in the text.)

¹²¹⁹²⁵²⁶²⁷ The Oskar Fischer Lecture Series https://dellmed.utexas.edu/units/mulva-clinic-for-the-neurosciences/oskar-fischer-lecture-series

³⁶¹¹¹⁵¹⁷¹⁸²⁸³⁰⁷²⁷³⁷⁴⁷⁵⁷⁶⁷⁷ RBN 59 (3) - Fischer – drusiform necrosis https://www.neuro.org.br/pdfs/RBN-59/RBN-593-SETEMBRO/RBN-593-SETEMBRO-30.pdf

⁴⁵⁹¹⁰³⁷⁶⁹⁸²¹⁰⁰¹⁰² Autophagy-lysosomal-associated neuronal death in neurodegenerative disease - PubMed https://pubmed.ncbi.nlm.nih.gov/39259382/

⁷¹²¹⁶²²²³²⁴²⁹³²⁶⁰⁶¹⁶²⁷¹⁷⁸⁷⁹⁸⁰⁸¹¹¹³¹¹⁷¹²¹¹²²¹²⁵ Frontiers | Historic evidence to support a causal relationship between spirochetal infections and Alzheimer’s disease https://www.frontiersin.org/journals/aging-neuroscience/articles/15.00046/full

Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, et al.. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 2010;141(7):1146-58. DOI 10.1016/j.cell.2010.05.008.

¹³ Oskar Fischer - Wikipedia https://en.wikipedia.org/wiki/Oskar_Fischer

¹⁴³⁹⁴⁰⁴¹⁴²⁴³⁴⁴⁴⁵ Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study - PubMed https://pubmed.ncbi.nlm.nih.gov/15751225/

²⁰²¹ Drawings of plaques by Fischer and Bonfiglio. (A) Drawing of a plaque... | Download Scientific Diagram https://www.researchgate.net/figure/Drawings-of-plaques-by-Fischer-and-Bonfiglio-A-Drawing-of-a-plaque-by-OskarFischer_fig1_7721991

³¹⁷⁰ [PDF] The past, present and future of Alzheimer's disease – part 1 - SciELO https://www.scielo.br/j/anp/a/jPM5p9hCmWNdsMHDKwnpMkP/?format=pdf&lang=en

³³ View of Aβ plaques | Free Neuropathology https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/3025/3006

³⁴ Faked Beta-Amyloid Data. What Does It Mean? | Science | AAAS https://www.science.org/content/blog-post/faked-beta-amyloid-data-what-does-it-mean

³⁵ 48 Alzheimer disease Images: PICRYL - Public Domain Media... https://picryl.com/topics/alzheimer+disease

³⁶ Autophagy - Wikipedia https://en.wikipedia.org/wiki/Autophagy

³⁸ Increased Neuronal Endocytosis and Protease Delivery to Early... https://www.jneurosci.org/content/17/16/6142

⁴⁶ Extensive Involvement of Autophagy in Alzheimer Disease https://academic.oup.com/jnen/article/64/2/113/2916595

⁴⁷ Autophagic/lysosomal dysfunction in Alzheimer's disease https://alzres.biomedcentral.com/articles/10.1186/alzrt217

⁵³⁹⁴⁹⁵ Nixon Publishes Review in Acta Neuropathologica https://www.cdr.rfmh.org/nixon-publishes-review-in-acta-neuropathologica/

⁵⁴ Autophagy–lysosomal-associated neuronal death in... https://pmc.ncbi.nlm.nih.gov/articles/PMC11418399/

⁵⁵⁵⁶⁵⁷⁵⁸⁵⁹⁸⁵⁸⁶⁹²⁹³¹⁰¹¹²⁰ Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques | Nature Neuroscience https://www.nature.com/articles/s41593-022-01084-8?error=cookies_not_supported&code=eddeebed-fbfb-490c-aac9ff019b64e967

⁶³¹¹⁵ Herpes simplex virus type I induces the accumulation of intracellular... https://www.sciencedirect.com/science/article/abs/pii/S0197458010005270

⁶⁴¹¹⁶ Herpes Simplex Virus type 1 inhibits autophagy in glial cells but... https://www.frontiersin.org/journals/microbiology/articles/655/full

⁶⁵⁶⁶⁹⁶⁹⁷ Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons - PubMed https://pubmed.ncbi.nlm.nih.gov/29246723/

⁶⁷ A Role for Presenilins in Autophagy Revisited: Normal Acidification... https://www.jneurosci.org/content/32/25/8633/tab-e-letters

⁶⁸¹¹⁴ Herpes simplex virus type 1 and Alzheimer's disease: the autophagy connection - PubMed https://pubmed.ncbi.nlm.nih.gov/18300070/

⁸³⁸⁴⁹⁰ Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr682-phosphorylated APP βCTF - PubMed https://pubmed.ncbi.nlm.nih.gov/37494443/

⁸⁸ Failure of lysosomal acidification and endomembrane network in... https://www.nature.com/articles/s12276-025-01579-x

⁸⁹ Review Disorders of lysosomal acidification—The emerging role of v... https://www.sciencedirect.com/science/article/abs/pii/S1568163716300800

⁹¹ Amyloid precursor protein carboxy-terminal fragments as catalyzers... https://www.cell.com/trends/neurosciences/fulltext/S0166-2236(25)00102-X

⁹⁸ Lysosomal lipid alterations caused by glucocerebrosidase... - Nature https://www.nature.com/articles/s41531-022-00397-6

⁹⁹¹⁰⁸¹⁰⁹¹¹⁸¹²⁴ Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson’s disease - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC6138580/

¹⁰³ “LRRK2: Autophagy and Lysosomal Activity” - PMC - PubMed Central https://pmc.ncbi.nlm.nih.gov/articles/PMC7262160/

¹⁰⁴¹⁰⁶ Increased LRRK2 kinase activity alters neuronal autophagy by... https://www.cell.com/current-biology/fulltext/S0960-9822(21)00305-5

¹⁰⁵ Saurabh Khasnavis | Rush University Medical Center | 9... - SciSpace https://scispace.com/authors/saurabh-khasnavis-4moa7mukzf

¹⁰⁷ The autophagy–lysosome pathway: a potential target in the... https://journals.lww.com/nrronline/fulltext/2025/01000/the_autophagy_lysosome_pathway__a_potential_target.13.aspx

Hull A, Atilano ML, Gergi L, Kinghorn KJ. Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson's diseases: insights for drug discovery. Philosophical Transactions of the Royal Society B: Biological Sciences 2024;379(1899). DOI 10.1098/rstb.2022.0381.

¹¹² Autophagic lysosome reformation dysfunction in glucocerebrosidase... https://academic.oup.com/hmg/article/25/16/3432/2525806

¹¹⁹ Lysosomal dysfunction in Down Syndrome and Alzheimer mouse... https://www.biorxiv.org/content/10.1101/2022.06.02.494546

¹²³ [PDF] Dr. Oskar Fischer's Curious Little Alzheimer's Germ - Scientia Ricerca https://scientiaricerca.com/srcons/pdf/SRCONS-01-00026.pdf

Genes named on this page: APP, amyloid precursor protein, APPβ; PSEN1, presenilin-1, Presenilin 1, PS1; LRRK2; V-ATPase (ATP6V), v-ATPase, vacuolar ATPase, vacuolar-ATPase; GBA, GBA1; GRN (progranulin), progranulin; ApoE, apoe4; TFEB; MAP1LC3B (LC3), LC3; TARDBP (TDP-43), TDP-43; SQSTM1 (p62), p62, SQSTM1; HTT (huntingtin), huntingtin; C9orf72; PSEN2, PS2; CTSB, Cathepsin B; CTSD, cathepsin D; SORL1; mTOR; TNF; PRNP, Prion Protein; BECN1, Beclin; TBK1; VCP.

The Master Theory